https://prohostf.smartnoticeboard.io/ 2026-07-02T05:15:34.312Z daily 1 https://prohostf.smartnoticeboard.io/articles 2026-07-02T05:15:34.312Z daily 0.9 https://prohostf.smartnoticeboard.io/categories 2026-07-02T05:15:34.312Z weekly 0.7 https://prohostf.smartnoticeboard.io/tags 2026-07-02T05:15:34.312Z weekly 0.5 https://prohostf.smartnoticeboard.io/faq 2026-07-02T05:15:34.312Z monthly 0.5 https://prohostf.smartnoticeboard.io/article/axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update 2026-06-30T10:38:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biontech-and-dualitybios-antibody-drug-conjugate-trastuzumab-pamirtecan-demonstrated-clinically-meaningful-efficacy-in-patients-with-her2-expressing-recurrent-endometrial-cancer 2026-07-01T02:56:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/neurocrine-acquires-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio 2026-07-01T08:02:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-approved-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions 2026-06-28T04:45:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders 2026-06-25T02:59:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/at-biogen-fda-approves-new-high-dose-regimen-of-spinraza-for-spinal-muscular-atrophy 2026-07-01T23:30:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rocket-pharmaceuticals-announced-fda-approval-of-kresladi-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i 2026-06-13T11:03:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-to-aquire-terns-pharmaceuticals-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia 2026-06-11T22:15:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/oryon-cell-therapies-reports-phase-1b-2a-data-showing-sustained-motor-improvements-in-people-with-parkinsons-disease 2026-06-30T10:38:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-imfinzi-product-has-been-approved-in-the-eu-as-first-and-only-perioperative-immunotherapy-for-patients-with-early-gastric-and-gastroesophageal-cancers 2026-06-12T11:51:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novartis-agrees-to-acquire-a-pan-mutant-selective-pi3k%ce%b1-inhibitor-strengthening-its-breast-cancer-pipeline 2026-03-20T16:37:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-approval-of-johnson-johnson-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide 2026-06-16T14:29:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pfizer-announces-positive-topline-phase-2-results-for-next-generation-cdk4-inhibitor-atirmociclib-in-second-line-metastatic-breast-cancer 2026-07-01T03:59:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron 2026-06-30T10:38:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bridgebio-pharma-product-bbp-418-demonstrates-consistent-efficacy-and-favorable-safety-profile-in-phase-3-fortify-interim-analysis-in-lgmd2i-r9 2026-05-22T17:49:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/zymeworks-inc-question-and-answer 2026-06-30T21:31:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy 2026-06-12T09:51:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/mirum-pharmaceuticals-provides-enrollment-update-for-azure-clinical-program-of-brelovitug-in-chronic-hepatitis-delta-virus 2026-06-12T12:11:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-on-compounded-semaglutide-teva-pharmaceutical-and-blackstone-life-sciences-announce-400-million-strategic-growth-capital-agreement-to-advance-duvakitug 2026-06-12T10:56:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-phase-3-clinical-trial-in-attr-cm 2026-07-01T09:57:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-q4-and-full-year-2025-financial-results-and-business-updates 2026-06-17T09:11:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-building-on-continued-efforts-to-expand-access 2026-02-24T18:01:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-evolves-human-health-operating-structure-to-support-portfolio-execution 2026-02-23T18:35:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-expands-u-s-footprint-with-more-than-1-billion-investment-in-next-generation-cell-therapy-manufacturing-facility-in-pennsylvania 2026-06-15T11:45:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-and-immunovant-inc-postivie-press-releases 2026-05-24T15:10:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bio-techne-corp-releases-second-quarter-fiscal-2026-results 2026-06-25T02:59:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofis-venglustat-met-all-primary-endpoints-in-a-phase-3-study-of-type-3-gaucher-disease 2026-02-02T16:18:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-2-phase-3-clinical-trial-in-attrv-pn 2026-06-07T03:49:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biocryst-pharmaceuticals-completes-acquisition-of-astria-therapeutics-expanding-leadership-in-hereditary-angioedema 2026-05-07T14:07:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/corcept-therapeutics-overall-survival-primary-endpoint-met-in-pivotal-phase-3-rosella-trial-of-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer 2026-06-12T13:14:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-announces-collaboration-with-microsoft-to-advance-ai-driven-early-detection-of-lung-cancer 2026-06-12T00:38:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gsk-enters-agreement-toacquire-rapt-therapeutics 2026-06-27T08:35:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-merck-announce-5-year-data-for-intismeran-autogene-in-combination-with-keytrudar-pembrolizumab-demonstrated-sustained-improvement-in-the-primary-endpoint-of-recurrence-free-survival-in-p 2026-05-15T00:26:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/china-approved-myqorzo-and-redemplo-two-sanofi-licensed-innovative-medicines 2026-05-06T22:00:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/two-companies-1-fda-extended-review-for-eli-lilly-oral-obesity-drug-orforglipron-2-wall-street-is-bullish-on-spyre-therapeutics-inc 2026-04-18T20:28:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sentynl-therapeutics-inc-announces-fda-approval-of-zycubo-for-menkes-disease-in-pediatric-patients 2026-07-01T11:11:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-life-sciences-joins-access-ad-a-major-initiative-funded-by-the-european-commission-through-the-clinical-evaluation-of-blarcamesine-as-part-of-a-precision-medicine-approach-in-alzheimers-disease 2026-01-13T13:22:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/abbvie-and-remegen-announce-exclusive-licensing-agreement-to-develop-a-novel-bispecific-antibody-for-advanced-solid-tumors 2026-06-21T11:50:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/insmed-inc-provides-business-update-at-44th-annual-j-p-morgan-healthcare-conference 2026-04-27T06:17:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rapport-therapeutics-announces-accelerated-initiation-of-rap-219-phase-3-program-expansion-of-epilepsy-portfolio-and-continued-progress-across-the-pipeline 2026-01-07T17:09:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/incyte-announces-positive-topline-results-from-the-pivotal-study-of-the-tafasitamab-as-first-line-treatment-for-diffuse-large-b-cell-lymphoma 2026-01-07T16:58:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-vanda-pharmaceuticals-product-nereus-for-the-prevention-of-vomiting-induced-by-motion 2026-01-02T17:01:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/happy-new-year-2026-and-more 2026-06-04T01:03:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp%e2%80%911-and-amylin-analogues-for-weight-management 2025-12-18T22:09:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biontech-closes-acquisition-of-curevac-n-v-including-subsequent-offering-period-to-strengthen-its-unique-position-in-the-mrna-field 2026-04-26T16:48:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/milestone-firm-receives-fda-approval-of-cardamyst-etripamil-as-first-and-only-self-administered-nasal-spray-for-adults-with-paroxysmal-supraventricular-tachycardia 2026-06-12T09:02:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors 2026-05-12T21:29:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-announces-partial-repurchase-of-1-00-convertible-senior-notes-due-2027 2025-12-12T15:59:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-announces-preliminary-data-from-exploratory-phase-2-trial-setmelanotide-demonstrating-positive-efficacy-signal-in-prader-willi-syndrome 2026-06-25T06:20:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/praxis-precision-medicines-alignment-with-fda-on-simplified-and-accelerated-registrational-pathway-for-elsunersen-in-early-onset-scn2a-developmental-and-epileptic-encephalopathy 2026-05-11T02:11:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/about-time-to-remember-and-today-and-many-days-before 2026-06-21T21:06:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-receives-u-s-fda-breakthrough-therapy-designation-for-zilganersen-for-alexander-disease 2026-06-29T10:44:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/harmony-biosciences-to-present-new-open-label-extension-data-from-phase-3-argus-trial-at-the-2025-american-epilepsy-society-annual-meeting 2026-06-22T18:15:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/roche-fda-clearance-with-clia-waiver-and-ce-mark-for-its-first-point-of-care-test-for-diagnosing-bordetella-infections-including-whooping-cough-pertussis 2025-12-03T16:10:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-question-and-answer-about-cogent-biosciences 2026-06-17T04:01:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eli-lilly-lowers-the-price-of-zepbound-tirzepatide-single-dose-vials 2026-06-13T04:44:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cogent-biosciences-has-excellent-news 2026-06-22T03:35:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aspen-neuroscience-announces-115-million-series-c-financing-to-accelerate-personalized-cell-therapy-programs-including-parkinsons-disease 2026-06-23T04:28:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-launches-introductory-self-pay-offer-for-wegovy-and-ozempic-for-199-per-month 2025-11-18T16:01:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-include-late-phase-antiviral-agent 2026-04-20T07:52:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-never-stops-bringing-new-data-to-heal-untreated-severe-diseases 2025-11-12T16:05:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cogent-biosciences-reports-positive-results-from-bezuclastinib-peak-phase-3-trial-in-gastrointestinal-stromal-tumors 2025-11-11T15:22:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-groundbreaking-pivotal-study-results-of-olezarsen-for-severe-hypertriglyceridemia-presented-as-late-breaker-at-aha-scientific-sessions 2026-07-01T11:45:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cidara-therapeutics-provides-corporate-update-and-reports-q3-2025-financial-results 2026-04-20T13:36:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/knowing-what-cidara-therapeutics-is-doing-for-the-seasonal-flu 2025-10-28T16:20:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bridgebio-pharma-reported-positive-phase-3-results-from-fortify-the-phase-3-pivotal-study-of-bbp-418-in-people-with-limb-girdle-muscular-dystrophy-type-2i-r9 2025-10-27T16:30:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-gsk-product-blenrepis-for-use-in-treatment-of-relapsed-refractory-multiple-myeloma 2025-10-24T16:59:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-approves-roche-gazyva-gazyvaro-for-the-treatment-of-lupus-nephritis 2025-10-20T15:58:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/u-s-fda-approves-boehringer-ingelheims-jascayd-nerandomilast-tablets-as-first-new-treatment-for-adults-with-idiopathic-pulmonary-fibrosis 2025-10-16T15:51:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-grail-inc-is-moving-up-more-than-usual-today 2026-04-26T07:46:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-db-oto-results-in-sustained-improvement-in-hearing-and-speech-perception-in-children-with-profound-genetic-hearing-loss 2026-06-13T12:26:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-announced-that-it-entered-into-a-definitive-agreement-to-be-acquired-by-novo-nordisk 2025-10-09T13:52:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/u-s-fda-lifts-clinical-hold-on-nuz-001-neurizon-lead-investigational-therapy-for-als 2025-10-06T19:39:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/genmab-to-acquire-merus-expanding-late-stage-pipeline-and-accelerating-into-a-wholly-owned-model 2025-09-29T16:53:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/uniqure-announces-positive-topline-results-from-pivotal-phase-i-ii-study-of-amt-130-in-patients-with-huntingtons-disease 2025-09-25T14:43:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-two-press-releases-in-the-past-2-days-from-grail-and-intellia-therapeutics 2026-05-21T10:41:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vectory-therapeutics-and-shape-therapeutics-both-private-firms-announce-option-and-license-agreement-to-advance-vectorized-antibodies-for-the-treament-of-neurodegenerative-diseases-using-an-aav5-deri 2026-06-13T19:08:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/in-data-presented-at-the-european-association-for-the-study-of-diabetes-and-neurodiabetis-meetings-lexicon-pharmaceuticals-product-pilavapadin-provided-meaningful-pain-reduction-in-adults-with-diabeti 2026-06-12T07:49:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eli-lillys-oral-glp-1-orforglipron-is-superior-to-oral-semaglutide-in-head-to-head-trial 2025-09-17T16:17:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jazz-pharmaceuticals-to-treat-h3-k27m-mutant-diffuse-midline-glioma 2026-05-04T08:37:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-is-taking-concrete-steps-to-reduce-opioid-misuse-addiction-and-overdose-strengthening-guidance-on-their-appropriate-use 2026-06-12T12:23:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-announces-proposed-offering-of-500-million-convertible-senior-notes-the-stocks-price-is-flying-up 2025-09-09T16:26:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-pharmaceuticals-libtayo-cemiplimab-plus-chemotherapy-results-at-five-years-reinforce-significant-and-durable-improvements-in-survival-outcomes-for-advanced-non-small-cell-lung-cancer 2025-09-09T16:18:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alkermes-detailed-positive-results-from-vibrance-1-phase-2-study-of-alixorexton-in-patients-with-narcolepsy-type-1-at-world-sleep-congress-2025 2026-04-29T09:29:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-product-olezarsen-significantly-reduces-triglycerides-and-acute-pancreatitis-events-in-landmark-pivotal-studies-for-people-with-severe-hypertriglyceridemia 2026-05-13T11:21:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-presentation-in-early-next-month-september 2026-06-23T06:32:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-new-approvals-of-covid-19-vaccines 2026-05-16T15:40:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bioarctic-and-novartis-sign-a-collaboration-and-license-agreement-using-braintransporter 2025-08-27T17:03:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/how-to-bring-undervalued-stocks-to-their-real-values-what-about-intellia-therapeutics-stock 2026-06-15T05:22:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-dawnzera-granted-us-fda-approval-as-first-and-only-rna-targeted-prophylactic-treatment-for-hereditary-angioedema 2026-06-26T22:35:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-announces-the-fda-acceptance-of-snda-for-setmelanotide-in-acquired-hypothalamic-obesity 2026-05-11T09:47:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/precigen-announces-full-fda-approval-of-papzimeos-the-only-currently-approved-treatment-for-adults-with-recurrent-respiratory-papillomatosis 2025-08-15T17:05:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/approval-of-brinsupri-for-the-treatment-of-non-cystic-fibrosis-bronchiectasis 2026-06-20T13:11:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/boehringer-ingelheim-helping-your-the-pets-to-be-healthy-and-live-longer 2026-06-13T07:42:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-q2-financial-and-study-results 2026-06-18T23:06:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-announced-its-second-quarter-2025-financial-results-yesterday 2025-08-08T13:11:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/praxis-precision-medicines-radiant-study-with-veratridine 2026-06-13T05:49:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/how-alnylam-pharmaceuticals-made-our-day-today-and-more 2025-07-31T12:44:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-imfinzi-granted-priority-review-and-breakthrough-therapy-designation-in-the-us-for-patients-with-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers 2026-06-26T17:15:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/klotho-neurosciences-to-expand-development-programs-beyond-neurology 2026-06-17T15:19:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gsk-announces-the-linked-by-lupus-optimal-care-initiative-to-help-support-individuals-with-lupus-in-the-us 2026-04-20T11:22:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eli-lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk 2025-07-25T14:48:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-product-gefurulimab-demonstrated-daily-living-of-adults-with-generalised-myasthenia-gravis-in-prevail-phase-iii-trial 2025-07-24T15:45:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-plans-to-invest-50-billion-in-america-for-medicines-manufacturing-and-rd-generated-in-the-us 2026-06-27T06:50:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/axsome-therapeutics-hosts-frontiers-in-brain-health-rd-day-reviewing-industry-leading-late-stage-cns-pipeline 2025-07-21T13:54:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/today-about-alnylam-pharmaceuticals-bristol-myers-squibb-and-intellia-therapeutics 2026-05-24T18:10:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/question-answer-about-kiniksa-pharmaceuticals 2026-06-14T08:01:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/about-making-sense-date-of-modernas-q2-financial-results-and-abbvie-agreement 2026-06-22T06:09:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-announces-european-commission-approval-of-alyftrek-a-new-once-daily-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2026-04-27T11:26:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-biontech-acquiring-curevac-is-good-news-for-biontech 2026-04-26T18:43:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-presents-positive-data-for-zimislecel-in-type-1-diabetes-at-the-american-diabetes-association-85th-scientific-sessions 2025-06-26T15:10:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cidara-therapeutics-announces-positive-topline-results-from-phase-2b-navigate-trial-evaluating-cd388-a-nonvaccine-preventative-of-seasonal-influenza 2026-04-20T05:03:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-announces-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-improved-overall-survival-in-patients-with-metastatic-colorectal-cancer 2025-06-23T14:03:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-we-believe-that-biontech-will-have-a-great-future 2026-06-13T18:32:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-receives-ec-approval-for-amvuttra-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy 2026-05-12T08:07:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-prohost-decided-to-pick-soleno-therapeutics-for-investment 2026-06-01T09:00:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-news-for-vera-therapeutics 2025-06-02T09:28:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-many-biotech-investors-believe-that-akero-therapeutics-will-soon-be-acquired-by-top-tier-company 2026-06-27T06:49:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/answering-questions-about-vera-therapeutics 2025-05-19T14:58:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-first-quarter-2025-financial-results-plus-corporate-update 2025-05-15T13:59:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/will-a-great-yesterday-erase-the-worlds-stress-after-the-u-s-and-chinas-agreement-over-tariffs-also-read-about-the-resurrected-cytomx-therapeutics 2026-06-30T06:06:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2025-financial-results 2025-05-07T12:18:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-reported-its-q1-2025-financial-results-and-highlights-recent-period-progress 2025-05-01T16:19:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-biotechnology-companies-news-plus-news-from-the-american-association-for-cancer-research-and-more 2026-06-20T23:52:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-origin-phase-3-trial-for-atacicept-in-igan 2025-04-16T17:16:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/asking-about-the-most-recent-halozyme-therapeutics-news 2026-05-16T20:06:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-and-how-the-stock-market-rallied-plus-a-combination-that-treated-a-severe-colorectal-cancer 2025-04-09T19:13:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-rytm-pharmaceuticals-stock-rallied-while-the-market-was-tumbling 2026-06-08T11:44:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-at-acc-2025-ozempic-with-once-weekly-semaglutide-1-0-mg-shown-to-improve-walking-distance-and-quality-of-life-in-adults-with-type-2-diabetes-and-peripheral-artery-disease-at-acc-2025 2025-04-03T16:53:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/u-s-fda-approved-alnylam-pharmaceuticals-product-qfitlia-forfor-treating-hemophilia-a-or-b-with-or-without-inhibitors 2025-03-31T16:39:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/wave-life-sciences-announced-what-could-be-excellent-news-in-treating-duchenne-muscular-dystrophy 2025-03-28T08:45:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bridgebio-pharma-to-present-cardiovascular-outcomes-data-in-patients-with-variant-and-wild-type-transthyretin-amyloid-cardiomyopathy-attr-cm-at-the-acc-annual-scientific-sessions 2025-03-24T16:12:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/results-from-ptc-therapeutics-latest-presentation 2025-03-24T16:00:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-approved-alnylam-pharmaceuticals-snda-for-amvuttra-a-treatment-for-cardiomyopathy-of-wild-type-or-hereditary-transthyretin-mediated-amyloidosis-in-adults-to-reduce-cardiovascular-mortality-cardiov 2025-03-21T12:59:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/two-companies-pyxis-oncology-financial-results-and-sarepta-therapeutics-unwarranted-selloff 2025-03-18T18:06:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/altimmune-astrazeneca-and-alnylam-pharmaceuticlas 2025-03-17T16:56:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-little-about-the-stock-market-and-some-news-from-johnson-johnson 2025-03-10T18:29:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-imfinzi-based-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-in-resectable-early-stage-gastric-and-gastroesophageal-junction-ca 2025-03-07T11:57:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ars-pharmaceuticals-announces-fda-approval-of-neffy-for-type-i-allergic-reactions-including-anaphylaxi-in-pediatric-patients 2026-06-12T18:40:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-receives-medicines-and-healthcare-products-regulatory-agency-marketing-authorization-in-the-uk-for-rsv-vaccine 2026-05-16T10:00:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio 2026-05-07T19:27:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/from-astrazeneca-and-daiichi-sankyo-enhertu-chmp-recommends-approval-in-the-eu-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocr 2026-06-25T14:00:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/new-data-advance-sanofis-scientific-leadership-across-innovative-treatments-for-inflammatory-skin-diseases 2025-03-03T16:11:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/can-cassava-sciences-resurrect-when-simufilam-is-used-to-treat-seizures-related-to-rare-neurodevelopmental-disorders-instead-of-alzheimers-disease 2025-02-28T17:42:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-press-release-highlights-significant-pipeline-progress-and-platform-innovation-at-rd-day 2026-05-12T08:39:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/conferences-announced-by-verona-pharma-and-grail-inc 2026-05-29T13:57:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-european-commission-granted-approval-to-gilead-sciences-seladelpar-in-combination-with-udca-for-the-treatment-of-primary-biliary-cholangitis 2025-02-21T16:55:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/q-a-about-alnylam-pharmaceuticals 2025-02-19T14:22:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/soon-many-treatments-for-life-threatening-diseases-will-become-old-history-time-to-select-biotech-companies-having-novel-advanced-technologies-and-products 2026-05-27T10:14:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-updates-on-extraintestinal-pathogenic-e-coli-vaccine-phase-3-clinical-study 2025-02-13T13:05:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/our-prohost-small-test-and-anavex-life-sciences-earning-report 2026-05-17T06:02:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/boehringer-ingelheim-product-nerandomilast-meets-primary-endpoint-in-phase-iii-study-in-progressive-pulmonary-fibrosis 2025-02-13T12:56:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eledon-pharmaceuticals-announces-use-of-tegoprubart-as-key-component-of-immunosuppression-regimen-in-its-second-transplant-of-a-genetically-modified-pig-kidney-into-a-human 2026-04-29T18:18:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/supernus-pharmaceuticals-announced-fda-approval-of-product-onapgo-for-the-treatment-of-motor-fluctuations-in-adults-with-advanced-parkinsons-disease 2025-02-05T15:39:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-therapeutics-chmp-issued-positive-opinion-for-subcutaneous-rybrevantamivantamab-co-formulated-with-enhanze-for-the-treatment-of-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer 2026-05-18T14:16:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-outstanding-and-promising-news 2025-01-31T16:10:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-daiichi-sankyo-and-astrazeneca-product-enhertu-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-disease-progression-after-one 2026-06-26T22:30:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/complete-preliminary-week-96-results-from-akero-therapeutics-efx-results 2026-06-26T19:22:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-successful-results 2026-06-23T21:09:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-acquires-global-rights-to-novel-next-generation-dual-baff-april-inhibitor 2025-01-13T16:48:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-announces-first-patient-dosed-in-phase-1-clinical-trial-to-evaluate-com503-as-monotherapy-and-in-combination-with-zimberelimab-in-advanced-solid-tumors 2025-01-29T16:43:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-therapeutics-reiterates-2024-financial-guidance-and-raises-2025-and-multi-year-financial-guidance 2026-05-18T12:45:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prescribing-specialists-confirm-success-of-verona-pharma-product-ohtuvayre-in-maintaining-copd-treatment 2026-06-25T06:19:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-reminder-verastem-oncology-announced-fda-acceptance-and-priority-review-of-the-nda-avutometinib-in-combination-with-defactinib-for-recurrent-kras-mutant-low-grade-sero 2026-05-10T19:03:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-announces-us-fda-approval-of-alyftrek-once-daily-next-in-class-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2024-12-23T13:26:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/revisiting-bluebird-bio-inc 2024-12-18T12:54:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/broadcom-incs-greatest-day 2024-12-13T11:03:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-european-regulatory-authority-adopts-positive-opinion-for-an-update-of-ozempic-label-to-reflect-risk-reduction-of-kidney-disease-related-events 2024-12-12T15:24:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-product-carvykti-improves-standard-of-care-therapies-for-relapsed-or-refractory-multiple-myeloma 2024-12-11T17:03:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/at-ash-2024-gilead-sciences-kites-yescarta-shows-its-car-t-cell-therapy-has-uniquely-durable-response-and-long-term-survival-after-five-years-in-patients-with-relapsed 2024-12-10T17:00:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/from-ash-vertex-pharmaceuticals-presented-positive-durability-of-the-gene-editing-casgevy-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia 2026-04-24T13:35:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intra-cellular-therapies-submits-supplemental-new-drug-application-to-the-us-fda-for-caplyta-treatment-of-major-depressive-disorder-as-adjunctive-therapy 2024-12-06T16:50:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nuvig-therapeutics-announces-161-million-series-b-financing-plus-its-progression-to-phase-2-with-novel-second-generation-immunomodulator 2026-06-23T06:52:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-tubulis-enter-exclusive-option-and-license-agreement-to-develop-antibody-drug-conjugate-adc-that-targets-solid-tumors 2024-12-04T16:45:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-keros-therapeutics-is-getting-200-million-upfront-payment-and-possibly-future-payments-from-takedathat-could-exceed-1-1-billion-and-more 2026-05-02T11:26:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ptc-therapeutics-global-license-and-collaboration-agreement-with-novartis-for-ptc518-huntingtons-disease-program 2026-06-17T18:11:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-product-trugap-abiraterone-and-androgen-deprivation-therapy-adt-improved-the-primary-endpoint-of-radiographic-progression-free-survival-in-pten-deficient-metastatic-hormone-s 2026-06-26T03:02:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-bridgebio-pharma-product-to-treat-adults-with-attr-cm-to-reduce-cardiovascular-death-and-hospitalization 2024-11-25T16:35:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/viking-therapeutics-presented-results-from-phase-2b-voyage-study-of-vk2809-in-biopsy-confirmed-nash-mash-at-the-75th-liver-meeting-2024 2024-11-20T16:31:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biogen-and-ucb-results-of-the-phase-3-phoenycs-go-study-evaluating-dapirolizumab-pegol-demonstrated-a-reduction-in-systemic-lupus-erythematosus-disease-activity 2026-05-11T01:46:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-announces-first-clinical-evidence-from-phase-1-study-that-an-in-vivo-crispr-cas9-based-gene-editing-therapy-may-favorably-impact-disease-progression-in-amyloidosis 2026-06-23T03:49:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/adaptimmunes-lete-cel-achieves-primary-endpoint-in-pivotal-trial-treating-advanced-sarcomas-and-other-solid-cancers 2026-06-16T18:20:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ptc-therapeutics-u-s-fda-approved-a-first-time-gene-therapy-administered-directly-into-the-brain-to-treat-children-and-adults 2024-11-14T12:18:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/altimmune-third-quarter-2024-financial-results-and-provides-business-update 2024-11-13T12:09:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biostem-technologies-reports-record-third-quarter-2024-revenue-of-82-6-million 2024-11-12T15:36:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-12T09:49:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-3rd-quarter-financial-results 2024-11-07T15:23:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-life-sciences-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimers-trial 2024-11-01T14:10:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/iterum-therapeutics-receives-us-fda-approval-of-orlynvah-for-the-treatment-of-uncomplicated-urinary-tract-infections 2026-06-13T22:34:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/some-stories-to-know-about-vera-and-viking-therapeutics 2024-10-29T13:18:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-announces-long-term-improvement-results-in-treating-bergers-nephritis 2024-10-28T13:59:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-positive-results-from-ntla-2002-in-crispr-gene-editing-treatment-for-hereditary-angioedema 2026-06-15T15:47:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-united-states-fda-approved-astellas-product-vyloytm-in-combination-with-fluoropyrimidine-and-platinum-containing-chemotherapy-for-the-first-line-treatment-of-adults-wi 2026-06-18T22:37:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-to-present-phase-3-data-highlighting-suzetrigines-potential-as-a-first-in-class-highly-selective-pain-signal-inhibitor-at-the-asa-ann 2024-10-18T16:49:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/u-s-fda-approves-abbvies-vyalev-foscarbidopa-and-foslevodopa-for-adults-living-with-advanced-parkinsons-disease 2026-06-21T19:58:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aligos-therapeutics-is-on-the-way-to-treating-mash-and-more 2024-10-16T18:59:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-launches-new-initiative-to-prevent-childhood-obesity-in-disadvantaged-urban-communities 2024-10-11T16:08:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-investigational-in-vivo-crispr-gene-editing-treatment-for-hereditary-angioedema 2026-06-22T05:01:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-strengthens-its-cardiovascular-pipeline-with-agreement-for-a-pre-clinical-novel-lipid-lowering-therapy 2026-06-26T13:29:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-announces-expanded-atacicept-development-program-in-multiple-autoimmune-kidney-diseases 2024-10-02T18:49:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-rolls-out-new-tecnis-odyssey-next-generation-intraocular-lens-offering-cataract-patients-precise-vision-at-every-distance-in-any-lighting 2024-09-30T19:07:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-united-states-fda-approved-bristol-myers-squibbs-cobenfy-a-first-in-class-muscarinic-agonist-for-schizophrenia-in-adults 2026-05-21T22:51:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pfizer-has-voluntarily-withdrawn-all-lots-of-its-sickle-cell-disease-reatment-oxbryta-from-worldwide-markets 2026-06-22T05:06:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-approved-intrabio-product-aqneursa-as-the-only-treatment-for-niemann-pick-disease-type-c 2024-09-26T10:37:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ucb-and-biogen-announced-positive-topline-results-phase-3-study-of-dapirolizumab-pegol-for-systemic-lupus-erythematosus 2026-06-20T14:49:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-product-sarclisa-approved-in-the-us-as-the-first-anti-cd38-therapy 2024-09-24T16:05:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aligos-therapeutics-announces-positive-topline-results-from-phase-2a-herald-study-of-alg-055009-for-the-treatment-of-mash 2024-09-20T16:50:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-product-fasenra-has-been-approved-in-the-united-states-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis 2026-06-27T10:39:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approves-novartis-kisqali-to-reduce-the-risk-of-recurrence-in-people-with-hr-her2-early-breast-cancer 2024-09-18T16:55:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazenecas-imfinzi-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2026-06-25T15:24:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-therapeutics-announced-fda-approval-of-roches-tecentriq-hybreza-with-enhanze 2026-05-18T17:46:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-product-tremfya-guselkumab-receives-u-s-fda-approval 2024-09-18T16:43:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/travere-therapeutics-announces-full-fda-approval-of-filspari 2024-09-11T17:58:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-genesis-therapeutics-announced-strategic-collaboration-to-discover-and-develop-novel-therapies 2026-05-16T21:55:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-announces-positive-results-of-its-product-rgx-121-for-hunter-syndrome 2024-09-05T15:00:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jeune-aesthetics-reversing-the-biology-of-aging-skin-to-meet-the-growing-demand 2024-09-04T18:00:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-discontinues-two-late-stage-keytruda-trials-and-other-important-information 2024-08-29T17:52:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/good-news-for-vertex-pharmaceuticals-and-for-crispr-therapeutics 2024-08-27T16:08:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-461-preventing-hiv-infection-and-treating-pbc 2026-06-27T19:41:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gileads-livdelzi-granted-accelerated-approval-for-primary-biliary-cholangitis-by-u-s-fda 2024-08-15T15:17:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/galderma-receives-u-s-fda-approval-for-nemluvio-for-adult-patients-living-with-prurigo-nodularis 2024-08-13T16:01:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytokinetics-reports-management-update-and-q2-2024-financial-results 2024-08-12T17:42:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-reports-q2-2024-financial-results-and-provides-business-update 2026-06-24T02:54:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-announces-q2-2024-financial-results-and-provides-corporate-update 2024-08-07T14:29:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/serious-is-the-impact-of-bad-circumstances 2024-08-06T16:48:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/adaptimmune-therapeutics-a-first-approved-treatment-of-unresectable-or-metastatic-synovial-sarcoma 2026-06-28T12:14:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-life-sciences-phase-iib-iii-trial-results-of-blarcamesine-presented-at-alzheimers-association-conference 2024-07-29T13:21:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/viking-therapeutics-reports-promising-news 2024-07-25T15:27:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-announces-positive-detailed-results-from-the-halos-study-of-ion582 2026-06-29T10:32:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pliant-therapeutics-positive-long-term-data-from-integris-psc-phase-2a-trial-of-bexotegrast 2024-07-16T11:36:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/lexeo-therapeutics-announces-positive-data-of-lx2006-for-the-treatment-of-friedreich-ataxia-cardiomyopathy 2024-07-16T11:26:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/kazia-therapeutics-announces-phase-11-111-clinical-trial-results-for-paxalisib-in-glioblastoma 2026-04-18T21:03:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/illumina-acquired-fluent-biosciences-to-accelerate-single-cell-analysis-and-discovery-to-a-broader-customer-base 2026-06-01T09:42:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/advanced-micro-devices-to-buy-the-largest-private-ai-lab-in-europe 2024-07-10T14:08:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-european-commission-approved-regeneron-product-dupixent-as-maintenance-treatment-for-adults-with-uncontrolled-copd 2024-07-05T16:03:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-and-orion-announce-mutual-exercise-of-option-providing-merck-global-exclusive-rights-to-opevesostat 2026-05-21T10:41:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/scg-cell-therapy-fda-approved-ind-application-of-product-scg142-to-initiate-phase-1-2-clinical-trial-for-a-next-generation-hpv-and-its-cancers 2024-07-01T14:24:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/mitsubishi-tanabe-pharma-america-announced-the-presentations-of-its-nd0612-in-parkinsons-disease-at-10th-congress-of-the-european-academy-of-neurology 2024-06-28T14:00:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/verona-pharma-announces-the-us-fda-approval-of-ohtuvayre-for-the-maintenance-treatment-of-copd 2026-06-24T01:08:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nurix-therapeutics-positive-results-from-ongoing-clinical-trial-of-nx-5948 2026-04-26T06:43:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-approval-of-the-company-argenx-product-vyvgart-hytrulo-for-patients-with-cidp 2024-06-24T14:42:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-reports-positive-topline-results-from-helios-b-phase-3-study-of-vutrisiran 2026-05-12T08:22:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sarepta-therapeutics-announces-expanded-us-fda-approval-of-elevidys-to-duchenne-muscular-dystrophy-patients 2026-05-05T06:56:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gileads-twice-yearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-for-hiv-prevention 2024-06-20T10:44:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/altimmune-important-upcoming-presentations 2024-06-18T16:57:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-announced-completion-of-a-successful-pre-bla-meeting-with-the-fda-for-rgx-121-treating-mucopolysaccharidosis-type-ii-mps-ii 2024-06-18T16:48:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-the-u-s-fda-approved-imfinzi-in-combination-with-carboplatin-and-paclitaxel-followed-by-imfinzi-monotherapy-for-adults-with-primary-advanced-or-recurrent-endometria 2026-06-27T06:50:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/broadcom-inc-announces-2q-fiscal-year-2024-financial-results-quarterly-dividend-and-stock-split-10-1 2024-06-14T09:32:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/asco-2024-innovent-biologics-delivers-oral-presentation-of-clinical-data-of-a-randomized-controlled-phase-1b-study-evaluating-ibi310-in 2024-06-13T10:40:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eli-lilly-product-tirzepatide-has-impressive-clinical-trial-results-from-treating-mash 2024-06-10T17:20:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-arcus-biosciences-treating-gastrointestinal-cancers 2024-06-06T16:59:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-about-agenus 2026-04-29T04:09:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-presented-positive-results-from-two-late-studies-of-investigational-product-donidalorsen 2026-06-30T20:09:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-460-treating-iga-nephropathy 2026-06-14T23:06:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/autonomix-medical-preclinical-study-successfully-demonstrates-that-nerve-ablation-can-slow-tumor-metastasis-in-pancreatic-cancer 2024-05-23T15:39:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-inc-announces-data-to-be-presented-at-2024-asco-annual-meeting 2026-05-15T23:58:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pivotal-data-about-efficacy-and-tolerability-of-arcturus-therapeutics-covid-19-vaccine-published-in-nature-communications 2024-05-22T12:18:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/verrica-pharmaceuticals-collaboration-and-license-agreements-opened-the-doors-wider-for-the-treatment-of-skin-diseases-other-than-molluscum-contagiosum 2026-05-01T10:54:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jennifer-schneider-elected-to-vertex-pharmaceuticals-board-of-directors-why-the-good-news 2024-05-15T18:06:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-improved-hearing-to-normal-levels-n-a-child-with-profound-genetic-deafness 2024-05-08T14:27:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-highlights-asgct-oral-presentation-and-announces-new-programs-utilizing-in-vivo-gene-editing-approach 2026-04-20T16:00:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-reports-first-quarter-2024-financial-results 2024-05-07T16:30:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytomx-is-rallying-today-the-firm-will-report-q1-2024-results-and-provide-an-initial-cx-904-phase-1a-clinical-data-update-on-may-8-2024 2024-05-01T16:31:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tg-therapeutics-stock-price-is-rising-as-q1-revenues-from-briumvi-u-s-have-exceeded-expectations 2024-05-01T14:44:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-appoints-scott-gangloff-as-chief-technology-officer 2026-06-19T19:38:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inmune-bio-inc-update-on-two-alzheimer-disease-patients-who-continued-to-receive-xpro-product 2026-05-09T22:58:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/u-s-fda-approved-pfizer-product-beqvez-a-one-time-gene-therapy-for-adults-livingwith-hemophilia-b 2026-06-22T20:00:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-and-treefrog-therapeutics-announced-licensing-agreement-and-collaboration-to-optimize-production-of-vertex-cell-therapies-for-type-1-diabetes 2026-04-29T00:00:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-pharmaceuticals-and-mammoth-biosciences-collaborate-to-pursue-next-generation-crispr-based-gene-editing-for-multiple-diseases 2024-04-25T16:04:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-immunity-bios-anktiva-for-the-treatment-of-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2024-04-23T16:34:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cerevel-therapeutics-announces-positive-results-for-tavapadon-in-phase-3-adjunctive-trial-for-parkinsons-disease 2026-05-02T02:28:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-announces-advancements-of-its-product-suzetrigine-for-acute-and-neuropathic-pain-and-more 2024-04-18T16:02:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/voyager-therapeutics-demonstrating-productivity-in-collaboration-with-neurocrine-to-advance-gene-therapies-for-neurological-diseases 2026-06-13T06:44:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/answers-about-vertex-pharmaceuticals-acquisition-of-alpine-immune-see-also-important-news-from-goya-therapeutics-on-als 2024-04-11T14:56:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/syndax-pharmaceuticals-positive-pediatric-data-from-pivotal-trial-of-revumenib 2024-04-09T15:03:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/madrigal-pharmaceuticals-announces-u-s-availability-of-its-newly-approved-product-rezdiffra 2024-04-09T14:47:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-to-acquire-shockwave-medical 2024-04-05T16:38:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biostem-technologies-press-release-and-conference-call-offered-encouraging-news 2026-04-22T03:34:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biostem-technologies-will-be-releasing-its-4q-2023-financial-results 2026-04-21T12:32:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/verrica-pharmaceuticals-announced-the-fda-granted-ycanthtm-new-chemical-entity-status-and-orange-book-listing 2026-05-14T09:42:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/abbvie-incs-two-different-yrt-positive-impacting-news 2026-06-15T17:09:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novo-nordisk-aims-at-acquiring-cardior-pharmaceuticals-strengthening-its-pipeline-in-cardiovascular-disease 2026-05-20T03:52:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/italfarmaco-received-fda-approval-for-duvyzat-for-the-treatment-of-duchenne-muscular-dystrophy 2024-03-22T20:26:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/illumina-stock-price-will-rebound-with-or-without-this-news 2024-03-22T09:45:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/selecting-new-small-biotech-firms-for-investment-krystal-biotech 2024-03-20T09:33:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/madrigal-pharmaceuticals-announces-fda-approval-of-rezdiffra-for-patients-with-nash-that-have-moderate-to-advanced-liver-fibrosis 2024-03-15T14:24:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/todays-bad-bear-market-and-cullinan-oncology-providing-2023-accomplishments-and-financial-results 2024-03-14T16:25:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/arcturus-therapeutics-reports-fourth-quarter-full-year-2023-financial-results-and-provide-corporate-update-and-hosts-a-conference-call-at-430-p-m-e 2024-03-07T14:36:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-reports-fourth-quarter-and-full-year-2023-results 2024-03-06T09:23:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biocardia-inc-reports-positive-interim-results-from-phase-iii-cardiamp-cell-therapy-heart-failure-trial 2024-03-04T13:44:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-reports-statistically-significant-histological-improvements-at-week-96-in-phase-2b-harmony-study 2026-06-05T01:25:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-459-nafld-nash 2026-06-20T20:27:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results 2026-05-02T09:21:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/krystal-biotech-announced-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-updates 2024-02-26T14:01:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-receives-chmp-positive-opinion-for-kalydeco-for-the-treatment-of-infants-with-cystic-fibrosis-ages-1-month-and-older 2024-02-23T18:32:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-financial-results-for-fourth-quarter-and-full-year-ended-december-31-2023-plus-all-you-need-to-know-about-this-firms-capabilities 2026-05-15T12:37:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results 2026-06-25T21:26:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/travere-therapeutics-fourth-quarter-and-full-year-2023-financial-results 2024-02-16T16:18:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/could-precision-biosciences-gene-editing-firm-become-the-only-company-to-cure-the-life-threatening-hbv-resistant-infection 2024-02-15T16:29:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-to-present-at-the-citi-2024-virtual-oncology-leadership-summit-see-also-crispr-therapeutics-advanced-steps 2026-04-22T05:15:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/two-pieces-of-news-from-crispr-therapeutics-today 2024-02-13T12:58:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-ec-approves-first-crispr-cas9-gene-edited-therapy-casgevytm-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia 2024-02-13T09:42:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-product-rgx-121-for-the-treatment-of-mps-ii-achieves-primary-endpoint 2024-02-09T10:08:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/madrigal-pharmaceuticals-announces-publication-of-the-phase-3-maestro-nash-trial-of-resmetirom-in-the-new-england-journal-of-medicine 2024-02-08T09:52:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/published-in-nature-communications-mink-therapeutics-agent-797-demonstrates-promising-results-in-the-treatment-of-severe-acute-respiratory-distress 2024-02-06T15:50:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-to-participate-in-guggenheim-healthcare-talks-6th-annual-biotechnology-conference-and-more 2024-02-02T12:27:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-publication-of-positive-interim-phase-1-data-for-ntla-2002-in-the-new-england-journal-of-medicine 2026-06-18T08:20:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/abbott-laboratories-launches-a-new-protality-brand-to-maintain-the-muscle-mass-of-adults-pursuing-weight-loss-by-various-means 2026-06-16T06:28:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-announced-positive-results-from-its-non-opioid-product-vx-548 2024-01-30T13:02:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/apellis-pharmaceuticals-announces-negative-chmp-opinion-on-pegcetacoplan-for-ga-in-the-european-union-and-its-plans-to-seek-re-examination-of-application 2024-01-27T09:36:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-presents-positive-72-week-data-showing-egfr-stabilization-in-the-phase-2b-origin-clinical-trial-ole-in-iga-nephropathy 2024-01-25T10:16:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/restoration-of-hearing-loss-to-be-presented-by-akouos-inc-a-wholly-owned-by-eli-lilly-at-the-association-for-research-in-otolaryngology-2024-midwinter-meeting 2026-04-20T02:06:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-to-acquire-inhibrx-inc 2024-01-23T12:46:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-announces-positive-results-from-phase-3-oasis-hae-study-of-investigational-donidalorsen-for-hereditary-angioedema 2026-07-01T09:20:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/lexaria-bioscience-unveils-extensive-planned-2024-glp-1-study-program 2024-01-16T11:50:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/okyo-pharma-limited-another-ophthalmology-firm-with-promising-eye-treatment 2026-04-16T14:26:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-provides-pipeline-and-business-updates-in-advance-of-upcoming-investor-meetings 2024-01-09T15:20:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cognition-therapeutics-ceo-issues-letter-to-shareholders 2024-01-04T11:37:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cymabay-therpaeutics-new-published-data-demonstrates-correlation-between-itch-cytokine-interleukin-31-reduction-and-pruritis-improve 2026-05-12T05:04:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/yes-compugen-stock-is-soaring-but-why 2024-01-02T16:25:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytokinetics-announces-positive-results-from-a-pivotal-phase-3-clinical-trial-of-aficamten 2023-12-29T14:44:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sarepta-therapeutics-submits-efficacy-supplement-to-expand-the-elevidys-label 2023-12-28T12:19:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-arcturus-therapeutics-holdings-pipeline-products-are-promising 2023-12-27T14:10:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunovent-altimmune-and-soleno-a-summery-of-three-firms-we-believe-have-promising-technologies-and-treatments 2026-04-17T20:46:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-life-sciences-product-blarcamesine-for-alzheimers-disease-receives-promising-news-from-the-ema 2023-12-20T11:09:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-invivyd-in-todays-december-18-2023-news 2026-05-19T22:09:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-458-obesity 2026-06-18T00:23:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/editas-medicine-and-vertex-pharmaceuticals-non-exclusive-license-agreement-in-cas9-gene-editing-technology 2023-12-13T11:58:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-stock-soars-pre-market-announces-positive-results-from-phase-2-study-of-vx-548-for-the-treatment-of-painful-diabetic-peripheral-neuropathy 2023-12-13T09:21:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-and-vertex-finally-gene-editing-therapy-has-been-approved-so-why-the-stock-selloff 2023-12-11T13:57:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-novartis-product-fabhalta-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria 2023-12-06T13:30:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/roche-announces-positive-phase-iii-results-for-inavolisib-combination-in-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2023-12-05T12:38:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd 2023-12-04T12:51:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/treating-obesity-altimmune-announces-positive-topline-results-from-the-momentum-48-week-phase-2-obesity-trial-of-pemvidutide 2023-12-02T10:52:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/abbvie-inc-to-acquire-immunogen 2026-06-15T21:04:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/carlisle-companies-inc-and-arcturus-therapeutics-granted-approval-in-japan-of-a-novel-self-amplifying-mrna-vaccine-for-covid-19 2023-11-28T18:11:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunovant-inc-positive-imvt-1402-results-that-would-confirm-best-in-class-potential-in-treating-autoimmune-diseases 2023-11-28T13:01:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-announced-us-patent-office-granted-a-patent-no-11813-242-entitled-a273-a-therapeutic-for-insomnia-anxiety-and-agitation 2026-05-17T05:48:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/for-migraine-patients-and-people-interested-in-new-migraine-results-abbvie-inc-is-published-in-the-lancet 2026-06-21T10:12:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-therapeutics-and-crispr-therapeutics-announce-authorization-of-the-first-crispr-cas9-gene-edited-therapy-casgevy 2023-11-16T13:05:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/about-the-fda-approval-of-eli-lilly-product-zepbound-for-obesity 2026-04-18T17:26:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/current-news-from-three-selected-biotech-firms 2026-06-16T03:24:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-announces-preclinical-data-at-the-american-heart-association-scientific-sessions-2023 2023-11-06T15:51:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/more-good-news-for-neurocrine-biosciences 2026-06-15T12:45:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunogen-reports-recent-progress-and-third-quarter-2023-financial-results 2023-11-02T11:48:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/good-news-for-crispr-therapeutics-and-vertex-pharmaceuticals 2023-11-01T09:51:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/beam-therapeutics-announces-agreement-for-lilly-to-acquire-beams-opt-in-rights-to-verve-therapeutics-base-editing-programs-for-cardiovascular-disease 2023-10-31T09:07:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anavex-life-sciences-reports-publication-in-scientific-journal-demonstrating-the-potential-of-anavex3-71-in-preventing-cognitive-decline-in-alzheimers-disease 2026-05-17T07:30:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/today-at-2-pm-akero-therapeutics-presented-at-the-h-c-wainwright-7th-annual-nash-virtual-investor-conference 2023-10-24T14:42:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-fda-clearance-of-its-systemically-administered-nda-of-ntla-2001-in-global-phase-3-trial 2026-05-19T15:09:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-receives-prime-designation-from-the-ema-for-ntla-2002-investigational-in-vivo-crispr-genome-editing-treatment-for-hereditary-angioe 2026-06-13T11:01:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-receives-fda-feedback-that-data-from-completed-phase-1-2-trial-of-ino-3107-can-be-used-to-submit-a-bla 2023-10-11T12:27:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-october-10-2023-press-release 2026-06-17T10:04:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/please-do-not-miss-aker-therapeutics-investor-conference-tomorrow 2026-06-16T05:12:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/apellis-announces-preliminary-u-s-net-revenues-of-approximately-74-million-for-syfovre-pegcetacoplan-injection-in-q3-2023 2023-10-06T16:30:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/neurocrine-biosciences-announced-positive-results-from-phase-3-cahtalyst-study 2026-06-09T08:58:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-announced-publication-in-the-lancet-gastroenterology-hepatology-of-harmony-phase-2b-trial-reults-for-nash 2026-06-19T20:34:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/soleno-therapeutics-announces-positive-top-line-results-of-its-product-dccr-for-the-treatment-of-prader-willi-syndrome 2026-05-19T01:52:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pliant-therapeutics-announces-positive-safety-and-exploratory-efficacy-data-from-phase-2a-integris-psc-clinical-trial-of-bexotegrast 2023-09-26T17:50:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-stock-holders-approved-the-firms-merger-with-biogen 2023-09-21T16:14:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/publication-of-two-cases-for-treatment-of-metastatic-pancreatic-cancer-by-carsgen-therapeutics-holdings-limited 2023-09-21T15:44:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/orchard-therapeutics-fda-acceptance-of-bla-application-for-product-otl-200-for-the-treatment-of-metachromatic-leukodystrophy 2023-09-18T15:47:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-457-discovering-the-root-causes-of-diseases 2026-06-27T10:01:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/neurocrine-biosciences-positive-top-line-data-from-phase-3-study-of-crinecerfont-in-adults-for-the-treatment-of-congenital-adrenal-hyperplasia 2026-06-13T19:43:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crinetics-pharmaceuticals-once-daily-oral-investigational-product-met-primary-and-secondary-endpoints-in-phase-3-treatment-of-acromegaly 2023-09-11T11:35:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alpine-immune-sciences-treating-iga-nephropathy-among-other-diseases 2023-08-31T12:44:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-therapeutics-enhanze-reduces-roches-tecentriq-treatment-time-to-7-minutes-from-30-60-minutes 2026-05-18T16:43:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-positive-results-in-phase-3-cabinet-trial-evaluating-cabozantinib-in-advanced-pancreatic-and-extra-pancreatic-neuroendocrine-tumors 2026-04-18T15:26:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/arcus-biosciences-participates-in-multiple-upcoming-investor-conferences-the-stock-boosted-today-see-also-todays-roche-press-release 2023-08-23T14:49:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-pharmaceuticals-eylea-hd-fda-approved-for-wamd-dme-and-dr 2023-08-21T13:50:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-biotechnology-revolution-from-nuvectis-pharmas-and-revolution-medicines-publication 2023-08-20T14:25:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-johnson-johnson-akeega-for-brca-positive-metastatic-castration-resistant-prostate-cancer 2026-04-22T22:34:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/xenon-pharmaceuticals-reports-2q-2023-financial-results-and-provides-corporate-update 2023-08-15T14:09:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cymabay-therapeutics-and-jazz-pharmaceuticals-conference-calls-today-at-4-30-pm 2026-05-04T17:39:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tg-therapeutics-important-conference-call-tomorrow-at-830-am 2023-07-31T17:48:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunogen-reports-recent-progress-and-2q-2023-financial-results-in-other-news-anna-berkenblit-md-senior-vp-and-cmo-is-stepping-down-from-her-position 2023-07-31T17:53:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-and-moderna-initiated-phase-3-study-evaluating-v940-in-combination-with-keytruda-for-patients-with-resected-high-risk-melanoma 2026-05-01T15:51:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-syndax-and-incyte-traded-up-in-todays-early-morning 2026-05-20T04:16:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozymes-therapeutics-positive-results-for-patients-with-cidp 2023-07-21T16:59:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/treating-cancers-resistant-to-all-drugs-a-priority-for-researchers-see-what-merck-and-kintara-have-done 2026-06-11T05:32:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-456-treatments-for-untreatable-diseases 2026-06-20T01:42:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-food-and-drug-administration-approved-biomarins-roctaviantm 2023-07-06T17:40:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-granted-celltrans-inc-approval-of-its-product-lantidra-for-the-treatment-of-type-1-diabetes 2026-04-23T07:23:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-biomarin-pharmaceutical-product-roctavian-for-adults-with-severe-hemophilia-a 2023-07-06T17:52:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bayer-bluerock-therapeutics-a-first-neuronal-stem-cell-therapy-to-show-positive-results-in-phase-i-clinical-study-for-parkinsons-disease 2023-07-06T17:46:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-455 2026-06-14T16:36:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aim-immunotech-announces-authorizations-from-competent-authority-and-ethics-board-in-the-netherlands-to-start-phase-1b-2-study-evaluating-ampligen-in-combination-with-astrazeneca 2023-06-27T12:17:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celmatix-inc-revolutionizing-fertility-treatments 2023-06-27T12:06:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/arbutus-biopharma-doses-first-patient-in-additional-treatment-arm-of-phase-2a-triple-combination-clinical-trial-that-includes-a-pd-1-monoclonal-antibody-nivolumab 2023-06-21T13:59:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vera-therapeutics-announces-positive-week-36-safety-and-efficacy-results-in-phase-2b-clinical-trial-of-atacicept-in-iga-nephropathy 2023-06-20T12:55:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/at-230-pm-today-the-chairman-of-the-federal-reserve-will-reveal-the-decision-about-interest-rates-see-also-good-news-from-gilead 2023-06-14T13:41:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-ut-southwestern-medical-center-is-enrolling-cancer-patients-in-phase-iii-tiger-pac-clinical-trial-from-renovorx 2023-06-01T13:52:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amylyx-pharma-informed-european-chmp-is-trending-toward-a-negative-opinion-for-conditional-marketing-authorization-of-amx0035-for-als 2023-05-30T18:09:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cullinan-oncology-to-present-first-monotherapy-clinical-data-forcln-619-at-asco 2023-05-26T11:44:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/our-eyes-are-on-reata-pharmaceuticals-today 2023-05-25T09:50:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intercept-pharmaceuticals-stock-is-halted-today-as-the-fda-advisory-committee-is-reviewing-obeticholic-acid-as-a-treatment-of-nash-precirrhotic-fibrosis 2026-04-26T22:53:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bio-techne-exodx-prostate-test-is-more-accurate-in-high-and-low-risk-patients-compared-to-standard-of-care 2026-04-28T19:20:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-therapeutics-presented-positive-preclinical-data-from-its-tslp-scf-bispecific-antibody-program-cdx-622-at-aai 2023-05-15T12:46:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/longeveron-has-encouraging-trial-results-for-hypoplastic-left-heart-syndrome 2023-05-09T19:28:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-curevac-stock-traded-up-in-a-bad-day-market 2023-05-08T18:05:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/chmp-adopts-positive-opinion-for-full-marketing-authorization-of-gileads-hepcludex-treatment-of-hdv 2023-05-04T13:02:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-releases-2023-corporate-responsibility-report-highlighting-the-advancement-of-its-environmental-social-governance-esg-priorities 2023-05-01T19:49:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunogen-obvious-recent-progress 2023-04-28T14:37:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-receives-chmp-positive-opinion-for-orkambi-in-children-with-cystic-fibrosis 2023-04-27T13:53:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/atea-pharmaceuticals-the-u-s-fda-granted-fast-track-designation-to-ateas-bemnifosbuvir-oral-antiviral-for-the-treatment-of-covid-19-resistsant-to-standard-of-care-products 2026-04-29T17:27:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/apellis-pharmaceuticals-validation-of-4-marketing-applications-for-pegcetacoplan-for-geographic-atrophy 2023-04-21T17:07:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cymabay-therapeutics-results-from-phase-3-study-of-seladelpar-in-patients-with-pbc-published-in-hepatology 2023-04-21T16:58:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-news-from-novartis-ms-product-kesimpta 2023-04-20T12:42:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/innoviva-the-fda-advisory-committee-unanimously-recommended-approval-of-sulbactam-durlobactam 2023-04-19T18:42:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-why-the-fda-accepted-to-review-keytruda-sbla-for-the-treatment-of-her2-negative-gastric-adenocarcinoma 2026-05-19T23:35:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-to-reach-full-commercial-control-of-antibody-beyfortus-against-rsv-in-us 2026-06-25T20:47:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-receives-fda-fast-track-designation-for-rgx-202-for-the-treatment-of-duchenne-muscular-dystrophy 2023-04-17T10:17:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-and-crispr-complete-submission-of-blas-to-the-us-fda-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia 2023-04-03T13:29:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tg-therapeutics-announced-positive-chmp-opinion-of-briumvitms-for-relapsing-forms-of-ms-in-adult 2026-05-01T00:50:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/new-study-from-neuvivos-np001-to-be-first-to-link-regulation-of-the-innate-immune-system-with-respiratory-function-in-als 2023-04-03T13:33:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-eu-chmp-agency-recommended-approval-of-tg-therapeutics-firms-briumvitm-for-relapsing-forms-of-ms-in-adults 2026-04-30T22:54:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-accepted-checkpoint-therapeutics-biotech-companys-bla-for-cosibelimab 2023-04-03T13:38:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/brainstorm-cell-therapeutics-another-clinical-stage-small-firms-product-for-als-devastating-disease 2023-03-27T15:32:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-new-licensing-agreement-between-vertex-pharmaceuticals-and-crispr-therapeutics 2023-03-27T10:32:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-recent-impacting-news 2023-03-25T11:45:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/23andme-teams-up-with-novartis-on-lipoproteina-education-for-its-customers 2026-07-01T09:37:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cymabay-therapeutics-clinical-trials-brought-proof-of-concept-of-its-technology-and-more 2023-03-21T17:56:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/as-expected-seagen-was-taken-over-the-buyer-is-pfizer 2026-05-12T18:01:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/promis-neurosciences-what-are-we-lookiing-for-in-a-bear-market 2023-03-11T11:06:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-the-current-interest-in-ventyx-biosciences 2023-03-11T09:09:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-announces-fda-clearance-of-ind-application-for-ntla-2002-therapy-for-the-treatment-of-hereditary-angioedema 2026-06-15T05:22:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/apellis-pharmaceuticals-a-biopharmaceutical-firm-that-we-like 2023-02-23T11:03:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-travere-therapeutics-stocks-did-not-fall-during-this-tuesdays-bad-market 2023-02-22T08:01:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/evaluating-regenxbio-clinical-performance-of-rgx-314-using-the-navxpress 2023-02-13T17:36:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/endogena-therapeutics-treating-retinitis-pigmentosa-and-other-devastating-degenerative-diseases 2023-02-13T15:36:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/xenon-pharmaceuticals-a-newly-selected-a-clinical-stage-firm-see-also-recently-sellected-clinical-stage-firms 2026-04-20T16:41:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-keytruda-plus-chemo-as-first-line-treatment-for-stage-iii-iv-or-recurrent-endometrial-carcinoma 2023-02-03T14:32:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytomx-therapeutics-why-does-good-news-from-this-firm-cause-its-stock-to-move-south-instead-of-north 2023-02-02T12:07:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/travere-therapeutics-may-soon-have-a-specific-treatment-for-igan-rare-disease 2023-02-02T11:50:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/xylocor-therapeutics-reported-positive-safety-and-efficacy-results-of-xc001-novel-gene-therapy-for-refractory-angina 2023-01-27T15:50:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tg-therapeutics-launched-fda-approved-product-briumvi-for-patients-with-relapsing-forms-of-ms 2023-01-27T11:27:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jazz-pharmaceuticals-and-zymeworks-product-zanidatamab-advance-the-treatment-of-her2-expressing-mga 2026-05-04T17:09:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/shoreline-biosciences-to-acquire-editas-medicines-ink-cell-franchise 2023-01-19T11:21:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion 2026-06-30T03:23:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-investors-have-enthusiasm-for-curevac-n-v-biopharmaceutical 2023-01-10T19:48:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activated-therapeutics 2026-06-30T06:03:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/stocks-outperforming-today 2023-01-05T13:44:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-promising-stocks-in-the-first-two-trading-days-of-2023 2026-06-17T15:37:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-still-way-undervalued 2026-06-20T15:11:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-kala-pharmaceuticals-stock-is-soaring 2022-12-28T14:39:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-note-to-our-followers 2026-06-23T03:50:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/madrigal-pharmaceuticals-and-akero-therapeutics-after-having-no-treatment-for-nash-we-now-have-two-products-expected-to-be-approved 2026-06-14T18:28:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-we-learned-this-morning 2022-12-13T16:49:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-iveric-bio-rallied-today 2026-06-30T15:01:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-inc-announces-3rd-quarter-2022-financial-results-and-an-update-on-clinical-development-programs 2022-11-09T15:24:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/searching-for-biotech-firms-with-novel-drugs-that-reached-clinical-stage-or-were-granted-early-fast-track-designation 2026-05-22T18:30:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/acumen-pharmaceuticals-new-effort-to-treat-alzheimers-disease-granted-fda-fast-track-designation 2026-07-01T14:53:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-and-macrogenics-announce-oncology-collaboration-to-develop-promising-bispecific-antibodies 2022-10-17T13:52:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-good-news-for-the-prohost-pick 2022-10-14T17:45:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/travere-therapeutics-treating-iga-nephropathy-and-focal-segmental-glomerulosclerosis 2022-10-14T17:33:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-452-treating-untreatable-disease-nash 2026-06-25T14:00:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amylyx-pharmaceuticals-announces-fda-approval-of-rellvrio-for-als-a-wierd-stock-market-reception 2022-09-30T21:25:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/from-biogen-and-eisai-lecanemab-confirmatory-phase-3-clarity-met-primary-endpoint-for-early-alzheimers-disease 2022-09-28T16:28:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/from-bluebird-bio-fda-accelerated-approval-for-skysona-gene-therapy-for-early-active-cerebral-adrenoleukodystrophy-cald 2026-07-01T02:29:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-excellent-news-from-ntla-2001-phase-1-clinical-trial 2026-06-20T10:15:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-and-akero-therapeutics-on-the-morning-of-september-15-2022 2026-06-19T01:33:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-efruxifermin-met-primary-endpoint-for-both-dose-groups-in-nash-patients 2022-09-13T18:41:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amylyx-pharmaceuticals-announces-fda-advisory-committee-supports-approval-of-amx0035-for-als 2022-09-08T16:01:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/iveric-bio-undeniable-promising-news-has-come-today 2022-09-06T18:03:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tg-therapeutics-promising-investigational-monoclonal-antibody-ublituximab-for-relapsing-form-of-m-s 2022-08-31T15:42:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-to-present-data-from-clinical-trial-of-ntla-2002-aimed-at-treating-hereditary-angioedema 2026-06-13T21:25:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fate-therapeutics-improving-on-cellular-therapies 2022-08-25T17:40:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-data-will-be-presented-by-regenxbio-on-august-30 2022-08-23T16:23:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-stock-rallies-following-improving-survival-of-pre-treated-hr-her2-metastatic-breast-cancer 2022-08-15T18:42:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-advisory-committee-will-soon-review-the-nda-of-amylyx-pharmaceuticals-product-amx0035-for-als 2022-08-11T15:52:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/htchmed-treating-advanced-mtastatic-colorectal-cancer-and-other-treatment-resistant-cancers 2022-08-10T17:38:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-announces-extension-of-review-period-for-omaveloxolone-nda-for-friedreichs-ataxia 2022-08-09T15:44:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-a-promising-acquisition-see-also-genmab-and-biontech-a-promising-expansion 2026-05-19T22:40:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-to-file-a-bla-using-the-accelerated-approval-pathway-for-rgx-121-for-hunter-syndrome 2022-08-03T16:01:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-combination-improving-the-treament-of-metastatic-melanoma-abbvie-improving-the-treatment-of-crohns-disease 2026-06-30T11:02:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seagen-and-astellas-pharma-announced-positive-topline-results-for-padcev-with-keytruda-as-first-line-treatment-for-advanced-urothelial-cancer 2026-06-13T20:00:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-rhythm-pharmaceuticals-stock-price-is-rebounding 2026-06-23T22:29:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/incyte-announces-the-fda-approved-its-opzelura-cream-for-the-treatment-of-vitiligo 2022-07-20T15:49:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/avista-therapeutics-partners-with-roche-to-develop-advanced-aav-gene-therapy-vectors-for-ocular-diseases 2026-04-26T19:16:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/shorting-biotech-firms-with-solid-fundamentals 2026-06-22T14:18:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/clene-inc-more-promising-news-for-als-patients 2022-07-14T17:03:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytomx-therapeutics-provided-an-important-strategic-update 2022-07-14T15:41:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-acquired-viacyte-inc-to-accelerate-its-potentially-curative-vx-880-programs-in-type-1-diabetes 2022-07-12T16:45:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/acquired-by-merck-or-not-seagen-will-sooner-or-later-outperform 2026-05-12T13:05:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/insilico-medicine-identifying-multiple-novel-therapeutic-targets-for-als-ai-driven-target-discovery-engine 2022-07-07T17:14:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-lifted-the-clinical-hold-on-vertex-product-vx-880-for-type-1-diabetes 2022-07-06T15:24:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/curevac-n-v-files-lawsuit-against-biontech-and-subsidiaries-seeking-fair-compensation-for-infringement-of-intellectual-property 2026-05-19T23:39:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-therapeutics-more-promising-results-in-treating-chronic-spontaneous-urticaria-refractory-to-antihistamines 2026-04-26T18:14:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/kite-pharmas-yescarta-approved-by-th-ec-for-adults-with-relapsed-or-refractory-follicular-lymphoma 2022-06-29T15:40:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-two-financing-transactions-with-pfizer-and-hercules-capital 2022-06-27T15:38:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/health-canada-approved-amylyx-pharmaceuticals-product-albrioza-for-amyotrophic-lateral-sclerosis 2026-05-30T17:05:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inflation-and-the-stock-market-see-also-news-from-asco 2026-04-28T16:06:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-deucravacitinib-demonstrates-promising-results-in-treating-systemic-lupus-erithematosus 2022-07-29T16:23:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-and-type-1-diabetes 2022-05-31T16:53:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-the-completed-acquisition-of-checkmate-pharmaceuticals-is-excellent-news-not-bad-news 2022-05-31T16:52:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-us-fda-approved-united-therapeutics-product-tyvaso-dpi-for-pah-and-ild 2022-05-27T18:49:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-pharmaceuticals-positive-new-results-of-lumasiran-in-advanced-pht1 2026-05-12T08:56:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-and-sanofi-fda-approves-dupixent-as-first-treatment-for-eoe 2022-05-23T16:16:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/karyopharm-therapeutics-chmp-recommended-approval-of-the-firms-product-nexpovio-for-multiple-melanoma-in-europe 2022-05-20T13:36:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-first-quarter-2022-financial-results-see-also-milestones-in-clinical-and-pipeline-development 2022-05-19T16:05:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-reminder-from-vir-biotechnology 2026-06-23T21:29:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bear-market-bad-market-unpredictable-market 2026-06-27T06:50:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eisai-and-biogen-inc-lecanemab-for-the-treament-of-early-alzheimers-diisease 2022-05-10T18:37:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-and-gilead-sciences-positive-news-for-two-undervalued-firms-in-the-prohost-portfolio 2022-05-05T16:22:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-pharmaceuticals-provided-successful-results-of-vx-880-for-type-1-diabetes 2022-05-02T15:44:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-repatha-studies-showed-sustained-reduction-in-low-density-lipoprotein-cholesterol-with-no-new-safety-findings 2026-06-28T03:04:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-remdesivir-is-the-first-and-only-approved-treatment-for-pediatric-patients-with-covid-19 2022-04-26T15:40:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/interesting-news-from-ptc-therapeutics-and-arcturus-therapeutics-holdings 2022-04-20T19:15:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-the-fda-lifts-partial-clinical-hold-on-magrolimab-studies 2022-04-13T15:17:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/promising-news-from-evotec-se 2026-06-01T12:20:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/promising-agreement-between-jazz-pharmaceuticals-and-werewolf-therapeutics 2026-05-04T10:49:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sunshine-biopharmas-new-mrna-therapeutics-killed-cancer-cells 2022-04-05T18:12:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-the-fda-approved-yescarta 2022-04-04T16:35:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-completed-rolling-nda-submission-of-omaveloxolone-for-friedreichs-ataxia 2022-04-02T08:29:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/news-from-vertex-and-cassava-two-prohost-portfolio-biotech-firms 2022-03-31T15:47:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-recent-news-from-incyte-eli-lilly-and-halozyme 2026-05-20T05:19:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/comprehensive-prohost-letter-449-reality 2026-06-23T19:07:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-happened-over-the-past-two-days-and-biotech 2026-04-26T10:54:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-statement-on-recent-u-s-patent-trademark-office-decision 2022-03-04T15:08:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/these-dangerous-world-circumstances-and-the-prohost-portfolio 2022-03-04T12:28:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-happens-to-intellia-therpaeutics-when-the-u-s-patent-and-trademark-office-changes-patent-decisions 2022-03-01T14:06:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/our-plan-as-the-stock-market-continues-to-plummet 2022-02-17T15:51:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/karyopharm-therapeutics-getting-a-boost-in-the-midst-of-a-chaotic-market 2022-02-14T15:12:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/who-forgot-about-enanta-pharmaceuticals 2022-02-11T16:52:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-milestone-for-regenxbio-treatment-of-wet-amd 2026-06-16T06:07:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-intellia-therapeutics-acquisition-of-rewrite-therapeutics-is-important 2022-02-07T15:52:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/some-ideas-about-a-falling-stock-market-day 2026-04-25T21:26:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/we-are-back 2026-04-29T09:41:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celularity-inc-nk-cell-therapy-cynk-001-receives-u-s-fda-fast-track-designation-for-aml-treatment 2021-12-28T13:15:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-and-encouraging-news-from-sutro-biopharma-inc 2026-04-19T08:31:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-authorized-emergency-use-of-pfizer-paxlovid-pills-against-covid-19 2021-12-25T08:52:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/comprehensive-prohost-letter-448 2026-06-23T21:48:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-arcus-biosciences-complete-closing-of-option-exercises-for-3-programs-see-also-hold-put-on-lenacapavir-due-to-vial 2021-12-22T12:34:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-cleared-the-ind-for-erasca-inc-product-eras-801-for-recurrent-glioblastoma 2026-05-01T00:32:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/arcturus-therapeutics-additional-updates-from-arct-154-and-arct-165-clinical-trials-and-more 2021-12-16T14:56:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/devastated-and-the-resurrected-good-biotech-firms-theravance-biopharma 2026-04-26T20:47:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-granted-fda-eua-for-long-acting-antibody-evusheld-for-pre-exposure-prophylaxis-of-covid-19 2026-06-26T22:30:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-to-collaborate-with-astrazeneca-in-treating-transthyretin-amyloidosis-with-ionis-product-eplontersen 2026-06-27T15:44:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-therapeutics-dosed-the-first-patient-in-a-phase-1-study-of-cdx-0159-for-prurigo-nodularis 2026-04-26T18:59:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/glaxosmithkline-and-vir-biotechnology-sotrovimab-retains-activity-against-omicron 2026-06-19T01:29:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-positive-results-from-otezla-phase-3-discreet-study-in-moderate-to-severe-genital-psoriasis 2026-06-28T03:04:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/great-news-vertex-pharmaceuticals-announced-successful-phase-2-study-results-of-vx-147 2021-12-01T10:30:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-omicron-variant-and-the-bizarre-stock-market-chaos 2021-11-30T17:35:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-announces-that-pfizer-reported-phase-2b-positive-results-of-vupanorsen-for-cardiovascular-risk-reduction-and-severe-hypertriglyceridemia 2026-06-27T15:57:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/takeda-pharmaceutical-product-livtencity-granted-approval-by-the-fda 2021-11-25T07:24:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-granted-regenxbio-investigational-gene-therapy-drug-rgx-202 2021-11-23T11:11:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/lets-talk-about-3-firms-with-important-news-cassava-sciences-vertex-pharmaceuticals-and-gilead-sciences 2021-11-19T17:33:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/arcus-biosciences-stock-price-skyrockets-following-gilead-sciences-decision-to-augment-their-partnership 2021-11-18T11:48:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/glaxosmithkline-and-vir-biotechnology-announced-u-s-govt-contracts-to-purchase-1b-of-sotrovimab-for-covid-19 2026-06-19T12:37:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-and-viacyte-inc-to-start-the-trial-of-first-gene-edited-cell-replacement-therapy-for-type-1-diabetes 2021-11-17T11:46:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-and-abbvie-agreement-see-also-gilead-sciences-and-everest-medicines-news 2026-06-22T00:32:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-and-ridgeback-biotherapeutics-u-s-government-to-purchase-1-4-m-additional-courses-of-molnupiravir-for-covid-19 2026-05-19T22:21:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-third-quarter-financial-results-and-other-company-updates 2021-11-08T12:00:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-to-highlight-ex-vivo-genome-editing-and-crispr-cas9-manufacturing-advances-at-ash 2021-11-06T12:19:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sangamo-therapeutics-preliminary-phase-1-2-data-showing-tolerability-and-sustained-elevated-%ce%b1-gal-a-enzyme-activity-in-patients-with-fabry-disease 2021-11-05T15:27:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/no-evidence-of-data-manipulation-in-technical-paper-foundational-to-cassava-sciences-lead-drug-candidate 2021-11-04T11:00:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-submits-maa-to-the-ema-for-chronic-kidney-disease-caused-by-alport-syndrome 2021-10-29T12:03:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-mercks-stock-price-soared-see-also-pulmotect-inhaled-pul-042-for-respiratory-symptoms-of-covid-19-and-fujirebio-agreement-with-addf 2021-10-28T17:46:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-merck-initiate-phase-2-study-evaluating-lenacapavir-and-islatravir-for-hiv-1 2021-10-26T13:41:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bausch-lomb-and-clearside-biomedical-fda-approval-of-xipere-for-macular-edema-associated-with-uveitis 2021-10-25T15:44:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/agenus-strategic-decision-to-withdraw-the-bla-for-balsitilimab 2021-10-22T16:09:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-receives-u-s-fda-orphan-drug-designation-for-ntla-2001-see-also-important-news-from-ultragenyx 2026-06-16T10:18:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-announces-presentations-highlighting-clinical-data-for-bardoxolone-and-disease-education-data-on-alport-syndro 2021-10-21T12:32:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rocket-pharmaceuticals-inc-announces-data-updates-at-the-esgct-conference-for-rp-l201-for-the-treatment-of-lad-i 2026-03-27T14:21:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-approved-oyster-point-pharma-inc-product-tyrvaya-to-treat-dry-eye-disease 2021-10-18T13:01:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-and-sparingvision-strategic-collaboration-to-develop-novel-ocular-therapies-see-also-why-crispr-therapeutics-news-is-good-not-bad 2021-10-14T14:42:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-good-news-about-rgx-314-for-diabetic-retinopathy 2021-10-11T13:31:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/dont-miss-the-enanta-pharmaceuticals-virtual-conference-on-october-19th-october-21st 2021-10-11T13:17:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/denali-therapeutics-positive-clinical-results-and-regulatory-progress-for-development-programs-in-als-see-also-ntla-tumbling-today 2021-10-08T12:15:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-authorized-to-initiate-phase-1-2-clinical-trial-of-ntla-2002-for-hereditary-angioedema 2021-10-06T10:52:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/atea-and-xenon-two-clinical-stage-firms-that-rallied-instead-of-crashing 2021-10-05T10:52:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-and-ridgeback-biotherapeutics-announced-successful-phase-3-trial-results-of-molnupiravir-for-mild-or-moderate-covid-19 2026-05-19T23:35:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/valneva-se-and-pfizer-inc-announce-further-positive-results-in-preventing-lyme-disease 2026-06-23T07:40:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-decided-plans-to-submit-omaveloxolone-nda-for-fa-in-q1-2022 2021-09-30T12:22:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-saphnelo-approved-in-japan-for-adult-patients-with-sle 2021-09-28T15:05:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-time-has-come-to-present-mirum-pharmaceuticals-inc 2021-09-27T15:30:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-world-health-organization-recommends-regeneron-pharmaceuticals-antibody-cocktail-for-covid-19 2021-09-24T14:25:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/can-excision-biotherapeutics-inc-cure-hiv 2021-09-24T14:07:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/encouraging-news-from-cassava-sciences 2021-09-22T11:05:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seagen-inc-and-genmab-announce-fda-accelerated-approval-for-tivdak-for-cervical-cancer 2026-06-19T01:34:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/comprehensive-prohost-letter-issues 2026-05-25T06:11:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-new-data-demonstrate-trodelvy-survival-benefit-in-metastatic-tnbc-see-also-galapagos-nv-news 2021-09-17T17:29:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-accepted-intellia-therapeutics-ind-application-of-ntla-5001-for-acute-myeloid-leukemia 2021-09-16T11:08:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-jounce-therapeutics-stock-is-outperforming-today 2026-05-07T06:25:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-and-abbvie-a-good-reason-for-rgnx-to-soar-today 2026-06-15T22:55:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-iveric-bio-stock-rallied-today 2021-09-10T11:03:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gain-therapeutics-inc-a-biotech-with-promising-treatments-for-neurodegenerative-diseases 2021-09-08T12:36:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/interesting-good-news-for-impel-neuropharma-and-migraine-sufferers 2026-06-17T00:50:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/can-fite-biopharma-has-encouraging-news-but-will-it-enthuse-investors 2021-09-02T17:35:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/positive-news-for-tcr2-therapeutics-the-u-s-fda-granted-orphan-drug-designation-togavo-cel-for-cholangiocarcinoma 2021-09-02T12:27:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/biomarin-pharmaceutical-inc-product-voxzogo-is-the-first-to-prevent-dwarfism-in-europe 2021-08-31T14:59:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-statement-regarding-plasma-p-tau-analysis-from-a-previously-disclosed-phase-2b-study-in-alzheimers-patients 2021-08-27T12:08:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/agenus-good-news-balstilimab-monotherapy-data-published-in-gynecologic-oncology 2026-06-15T23:24:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-issued-a-response-to-claims-posted-after-market-yesterday-see-also-cassava-sciences-good-news 2021-08-25T10:45:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cara-therapeutics-and-vifor-pharma-announce-us-fda-approval-of-korsuva 2021-08-24T14:07:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/axsome-therapeutics-treating-major-depressive-disorder-vivos-therapeutics-improving-the-treatment-of-sleep-disorders 2021-08-25T10:51:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-us-fda-granted-fast-track-designation-to-sutro-biopharma-inc-product-stro-002 2021-08-18T16:58:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-virpax-pharmaceuticals-stock-soared-on-two-consecutive-days 2021-08-18T16:15:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/beigene-and-eusa-pharma-product-qarziba-approval-from-china-nmba 2026-06-15T14:48:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/travere-therapeutics-positive-trial-results-of-its-product-sparsentan-in-treating-igan 2021-08-16T16:44:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-inc-q2-business-updates-and-financial-results 2021-08-13T14:47:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-a-biotechnology-companies-to-remember-and-appreciate 2026-06-25T14:01:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-two-stories-updated-the-news-of-its-clinical-programs-and-finances 2021-08-11T17:37:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/agenus-inc-corporate-update-and-financial-results-for-q2-2021-see-also-why-intellia-was-down-today 2026-04-29T17:27:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-446-a-reevaluation-of-prohost-biotechs-picked-firms 2021-08-10T11:40:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-fda-accepts-exelixis-snda-of-cabometyx-for-priority-review 2021-08-06T14:33:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novartis-announces-the-lift-of-the-partial-clinical-trial-hold-see-also-plans-to-initiate-a-new-sma-study 2021-08-17T10:57:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-to-acquire-translate-bio-advancing-mrna-technology-see-also-cassava-sciences-q2-financial-results 2021-08-03T14:43:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-a-big-step-towards-improving-the-lives-of-sle-patients-and-more-on-cassava-sciences 2026-06-27T17:12:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-good-news-and-an-unwarranted-sell-off-a-new-drug-approval-for-bristol-myers-squibb-and-immunogen-quarterly-results 2021-08-02T14:15:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-inc-todays-press-releases 2021-07-29T14:55:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/glaxosmithkline-and-vir-biotechnology-announce-joint-procurement-agreement-with-the-ec-for-covid-19-treatment 2026-06-20T15:49:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-announces-positive-data-with-savadx-from-a-randomized-controlled-phase-2b-study-of-simufilam 2021-07-26T10:28:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-receives-approval-for-skysona 2026-06-15T10:28:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-stock-soared-see-also-the-resurrection-of-sunesis-pharmaceuticals 2021-07-21T17:04:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immunome-inc-stock-rallied-after-announcing-it-neutralized-sars-cov-2-delta-variant 2026-04-19T04:24:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-cytokinetics-stock-price-soared-in-a-bad-market-day 2021-07-19T14:36:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-steps-forward-taken-by-vir-biotechnology-and-separately-by-compugen 2026-06-19T01:28:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/encouraging-news-from-hoth-therapeutics-and-kintor-pharmaceutical-ltd-about-treating-acne-and-alopecia 2021-07-14T12:49:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-announced-janssen-received-u-s-fda-approval-of-darzalex-faspro 2026-06-19T07:22:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-portfolio-7-companies-behind-the-biotech-revolution 2026-04-26T10:40:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-celldex-therapeutics-stock-is-soaring 2026-04-25T21:11:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/important-news-and-results-from-akero-therapeutics-and-bluebird-bio 2021-07-09T11:41:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/iveric-bio-receives-fda-agreement-under-spa-for-zimura-in-gga 2021-07-06T09:32:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/trxade-health-subsidiary-bonum-health-signed-a-telemedicine-service-distribution-deal-with-big-y-pharmacy-see-also-innate-pharma 2021-07-01T12:16:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-and-regeneron-pharmaceutials-yes-it-is-a-miracle 2026-04-26T08:53:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-promising-clinical-data-from-ongoing-trials-for-chronic-hbv-infection 2026-06-19T01:28:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-therapeutics-good-news-about-approvals-see-also-arrowhead-pharmaceuticals-has-good-trial-results-for-liver-diseases 2021-06-23T13:39:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/blackstone-announces-the-launch-of-a-new-company-with-intellia-therapeutics-and-cellex-cell-professionals-gmbh 2026-05-20T05:30:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/auris-medical-holding-has-encouraging-results-addressing-the-unmet-needs-of-atll 2026-05-01T06:46:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/blueprint-medicines-receives-an-fda-approval 2026-06-29T22:17:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-yescarta-fda-approved-for-relapsed-or-refractory-indolent-fl 2026-06-24T10:52:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jounce-therapeutics-inc-achieves-first-milestone-in-exclusive-license-agreement-with-gilead-sciences-for-jtx-1811 2026-05-04T10:38:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/veracyte-inc-exciting-news-about-nmcrpc-published-online 2026-05-27T14:43:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tthe-fda-approval-of-biogens-alzheimers-disease-drug-and-how-cassava-sciences-alzheimers-disease-drug-differs 2021-06-12T13:45:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-us-fda-approves-vertex-pharmaceuticals-trikafta-for-children-with-cystic-fibrosis-aged-6-to-11-with-certain-mutations 2021-06-09T11:10:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/fda-lifts-clinical-holds-on-bluebird-bio-gene-therapies-in-clinical-trials 2026-07-01T02:25:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-gene-editing-product-ntla-2001-a-dream-on-its-way-to-becoming-reality 2021-06-04T12:05:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bridgebio-pharma-has-promising-news 2021-06-02T17:13:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-merck-kgaa-darmstadt-germany-paid-sutro-biopharma 2021-06-01T13:45:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-fda-approves-lumakras-for-patients-with-kras-g12c-mutation 2026-06-28T03:04:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/glaxosmithkline-and-vir-biotechnology-announce-eua-from-the-us-fda-for-sotrovimab-in-treating-mild-to-moderate-covid-19 2026-06-09T04:02:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aptevo-therapeutics-inc-product-apvo436-improves-the-treatment-of-resistant-aml-and-mds 2021-05-27T12:56:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prilenia-therapeutics-pridopidine-product-for-huntingtons-and-lou-gehrigs-diseases-could-be-promising 2021-05-25T17:27:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/recursion-pharmaceuticals-a-step-forward-towards-improving-cdifficile-treatment 2021-05-25T16:52:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/annovis-bio-inc-very-encouraging-trial-results-in-neurodegenerative-diseases 2026-04-26T21:11:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-good-news-from-the-fda-regarding-omaveloxolone-for-friedreichs-ataxia 2021-05-19T13:49:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-agreement-between-bristol-myers-squibb-and-agenus 2021-05-19T11:18:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/more-vaccines-from-glaxosmithkline-one-with-sanofi-and-another-with-curevac 2021-05-17T12:41:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-and-amgen-product-tezepelumab-seems-to-overcome-the-resistance-to-severe-asthma-to-current-treatments 2026-06-28T03:04:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-first-quarter-financial-results-accomplishments-and-future-plans 2021-05-13T11:54:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-awarded-nih-grant-see-also-intellia-therapeutics 2021-05-12T12:45:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sutro-biopharma-first-quarter-financial-results-business-highlights-and-more 2026-04-26T15:44:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/adc-therapeutics-moving-from-a-development-stage-firm-to-a-revenue-generating-frrm 2026-06-27T08:38:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/editas-medicine-business-highlights-and-financial-results-reported 2021-05-05T12:55:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-prohost-portfolio-plus-5 2026-06-21T02:34:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-conference-call-information-see-also-compugen-announcements 2026-04-27T23:17:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-tagrisso-recommended-for-marketing-authorization-in-the-eu-for-early-stage-egfrm-nsclc 2021-04-29T10:34:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-and-astrazeneca-nirsevimab-protects-healthy-pre-term-and-term-infants-from-rsv 2021-04-27T13:10:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-and-crispr-the-ema-granted-prime-designation-to-ctx001 2021-04-26T11:24:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-therapeutics-see-also-more-of-your-questions-answered 2026-04-26T19:16:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-eisai-submitted-an-application-to-japans-pmda-for-approval-for-filgotinib-for-uc 2021-04-23T12:25:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-chmp-recommended-additional-approval-onureg 2021-04-23T11:03:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/humanigen-inc-product-lenzilumab-combination-with-car-t-in-dlbcl-protects-from-severe-cytokine-syndrome 2026-06-24T09:51:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-guidance-for-simufilam-see-also-its-first-quarter-2021-financial-results 2021-04-21T14:01:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-and-glaxosmithkline-ema-started-review-of-vir-7831 2026-06-26T08:53:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amylyx-pharmaceuticals-continuing-to-offer-promising-results-in-treating-als 2021-04-20T11:54:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/curevac-n-v-prohost-portfolio-plus-3 2022-04-02T09:11:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-dna-vaccine-candidate-ino-4800-has-promising-results 2026-04-19T10:26:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-another-accelerated-cancer-approval-from-the-fda 2021-04-14T14:16:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-granted-breakthrough-therapy-designation-to-vtv-therapeutics-for-type-1-diabetes-product-ttp399 2021-04-13T13:11:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-portfolio-plus-re-working-some-evaluated-biotechnology-firms 2026-05-15T21:58:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-fda-fully-approves-trodelvy-for-metastatic-tnbc 2021-04-08T12:01:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-latest-news-also-transmedics-may-improve-on-heart-transplants 2021-04-07T13:02:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-announces-more-good-news 2021-04-05T13:06:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-cabometyx-now-approved-in-europe-for-first-line-treatment-of-rcc 2026-04-19T01:01:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/illumina-acquisition-of-grail-a-challenging-story-that-boosted-ilmns-stock-price 2026-06-03T14:38:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rubius-therapeutics-a-biotech-firm-we-long-to-discover 2021-03-30T14:32:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-portfolio-plus-your-questions-our-answers-2 2026-06-09T10:05:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-important-current-presentations 2021-03-25T11:44:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novartis-announced-positive-results-of-177lu-psma-617-in-advanced-prostate-cancer-patients 2021-03-24T11:04:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-445-a-flashback-and-future-projections 2026-06-27T15:07:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/negative-news-from-ionis-pharmaceuticals-phase-3-trial-for-hd 2021-03-23T14:11:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/curevac-has-very-interesting-plans 2021-03-22T12:52:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-to-supply-half-a-million-additional-doses-of-the-potential-covid-19-antibody-treatment-azd7442-to-the-u-s 2026-06-22T17:49:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/immutep-ltd-evaluating-the-safety-and-efficacy-of-eftilagimod-alpha-in-combination-with-mercks-keytruda 2021-03-16T13:35:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-merck-long-term-oral-hiv-combination-treatment 2021-03-15T12:08:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/anixa-biosciences-why-this-firm-outperformed-today 2026-05-06T10:27:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aveo-oncology-the-fda-approved-fotivda-for-adults-with-relapsed-or-refractory-advanced-rcc 2021-03-11T12:20:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-and-glaxosmithkline-gsk-independent-data-monitoring-committee-recommends-stopping-phase-3-comet-ice-trial-early 2026-06-18T07:53:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-updated-findings-of-aml-in-lentiglobin-for-scd 2021-03-10T13:04:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-its-all-about-common-sense 2021-03-09T14:37:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-444-the-first-prohost-letter-in-2021 2026-06-18T21:54:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-reasons-why-ovid-therapeutics-stock-outperformed-today 2021-03-03T13:13:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-approved-kempharm-inc-azstarys-for-adhd 2021-03-03T10:49:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aslan-pharmaceuticals-a-small-firm-with-early-promising-results-for-atopic-dermatitis 2021-03-01T12:17:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-johnson-johnson-covid-19-vaccine-increasing-the-pressure-on-the-virus 2021-03-01T11:22:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-qiagen-and-inovio-pharmaceuticals-partnership-extension 2021-02-25T11:47:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-covid-19-vaccine-voting-tomorrow-with-expected-approval-on-saturday 2026-04-30T23:31:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-good-news-during-bad-market-days 2021-02-23T14:52:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-pharmaceuticals-good-news-during-bad-market-days 2021-02-23T14:38:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-good-news-during-bad-market-days 2021-02-23T14:13:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novavax-is-bringing-its-covid-19-vaccine-to-the-worlds-markets 2021-02-19T14:09:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-reasons-for-the-immunome-inc-stock-rally 2026-05-12T21:59:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/is-there-a-possible-comeback-for-nektar-therapeutics 2021-02-18T10:44:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vir-biotechnology-and-glaxosmithkline-expanded-agreement 2026-06-22T03:50:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-temporarily-suspends-studies-of-lentiglobin-gene-therapy-for-scd 2026-06-15T04:54:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-has-much-good-news-is-the-market-paying-attention 2021-02-20T11:21:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-cassava-sciences-inc-stock-opened-down-today-see-also-mirati-therapeutics-and-md-anderson-interesting-collaboration 2021-02-10T11:54:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-program-progress-and-its-expected-milestones-for-2021 2021-02-09T10:42:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/researchers-at-the-childrens-hospital-of-philadelphia-are-improving-gene-therapy-vectors 2021-02-09T10:43:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/spark-therapeutics-gene-therapy-spk-8016-promising-results-for-severe-hemophilia-a 2026-04-20T14:53:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-simufilam-improved-cognition-and-behavior-of-alzheimers-patients 2021-02-02T11:14:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-is-still-the-king-of-the-biotech-sector 2021-01-30T08:33:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-covid-19-vaccine-produced-neutralizing-titers 2026-05-15T09:58:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/casi-partner-bioinvent-restores-rituximab-capability-to-succeed-in-treating-indolent-relapsed-or-refractory-b-cell-non-hodgkins-lymphoma 2021-02-01T13:47:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/aurinia-pharmaceuticals-fda-approved-lupkynis-for-active-ln-in-adults 2021-01-27T11:30:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/merck-has-interesting-news-and-impressive-results 2021-01-26T11:25:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/viiv-healthcare-the-us-fda-approved-cabenuva-for-adults-with-hiv-1 2026-04-19T03:29:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-fda-approved-cabomayx-in-combination-with-opdivo-for-rcc 2021-01-23T16:56:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-why-the-great-expectations-from-this-firm 2021-01-22T16:10:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sutro-biopharma-dosed-the-first-patient-with-stro-002 2021-01-21T11:00:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-news-abourt-alport-syndrome-and-fa 2021-01-19T14:46:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-blue-the-appealing-decision-to-separate-its-severe-genetic-disease-and-oncology-businesses-into-independent-publicly-traded-firms 2026-06-30T17:47:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/la-jolla-pharmaceutical-company-announced-an-exclusive-licensing-agreement-for-giapreza-and-xerava-in-europe 2021-01-12T11:51:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/underlining-exelixis-bright-future-the-2020-financial-results 2021-01-11T12:13:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/for-those-still-asking-why-crispr-gene-editing-stocks-are-soaring-intellia-therapeutics 2021-01-07T14:18:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-successful-results-from-phase-3-trial-with-setmelanotide-in-treating-obesity-caused-by-the-genetic-bbs 2026-06-07T03:49:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-exciting-news-published-in-the-lancet 2020-12-24T13:51:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-advancing-its-gene-therapy-pipeline-and-its-rare-neurodegenerative-disease-platform-with-non-dilutive-capital 2020-12-23T15:14:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-exclusive-license-agreement-with-astrazeneca 2020-12-28T11:18:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-good-news-for-mantle-cell-lymphoma-and-more 2020-12-16T13:47:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-reinforcing-the-promise-to-potentially-cure-disease 2020-12-15T14:29:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/acquisitions-that-make-sense-azn-alxn-and-gild-myr 2020-12-14T14:47:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/editas-medicine-inc-is-joining-its-two-sisters-on-the-road-toward-great-performances 2020-12-10T14:57:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-biotechnology-industry-the-prohost-letter-443 2026-05-06T10:07:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-reata-pharmaceuticals-stock-is-down-read-also-news-from-exelixis 2020-12-02T12:25:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-intellia-therapeutics-and-modernas-stocks-moved-south-yesterday 2026-05-16T12:30:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-announced-the-first-patient-was-dosed-with-rgx-111-for-mucopolysaccharidosis-type-i-mps-i 2020-12-01T10:49:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-imcivree-approved-for-genetic-obesity 2026-06-23T19:52:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-latest-from-reata-pharmaceuticals-see-also-prohost-picks-which-reached-the-moon-in-todays-trading 2020-11-27T19:41:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-us-fda-approved-alnylam-oxlumo-to-lower-urinary-oxalate-levels-in-pediatric-and-adult-patients-with-ph1 2020-11-24T16:20:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-new-covid-19-vaccine-showing-successful-results 2026-05-19T22:03:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-pharmaceuticals-granted-fda-eua-for-its-covid-19-antibody-cocktail 2026-04-30T18:34:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pfizer-and-biontech-submitted-an-eua-to-the-fda-for-bnt162b2 2026-05-19T22:06:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-lenacapavir-deserves-the-fda-granted-breakthrough-therapy-designation 2020-11-19T13:02:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ptc-therapeutics-many-attractive-achievements-and-approvals 2020-11-18T15:43:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-to-proceed-with-phase-2-trial-of-ino-4800-for-covid-19 2020-11-17T10:45:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-successful-covid-19-vaccine-results 2020-11-16T13:26:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-inc-future-growth-and-its-covid-19-vaccine-candidate 2026-06-10T11:16:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-first-in-class-antibody-for-a-difficult-to-treat-stomach-cancer 2020-11-11T13:43:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-thrid-quarter-financial-results-and-sickle-cell-disease 2020-11-10T08:39:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pfizer-and-biontech-vaccine-candidate-against-covid-19-achieved-a-sweet-success 2020-11-09T09:50:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-professor-emmanuelle-charpentier 2020-11-06T15:36:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-compugen-is-a-favorite-biotechnology-firm 2020-11-06T11:26:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-we-expect-to-hear-at-the-regenxbio-conference-call-today 2020-11-04T13:57:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-achievements-and-q3-financial-results 2026-06-24T06:10:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/imminent-november-announcements-of-important-quarterly-results 2026-06-26T10:19:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-expect-a-lot-from-compugen-and-regenxbio 2020-10-27T11:23:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/news-from-astrazeneca-experimental-vaccine-azd1222-for-covid-19 2020-10-26T11:11:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-us-fda-approves-gilead-sciences-antiviral-veklury-remdesivir-for-covid-19 2020-10-23T12:39:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-pharmaceuticals-news-about-als-treatment-attempts 2026-05-13T11:32:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-immuno-oncology-results-are-good 2020-10-21T15:05:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-great-game-changer-in-the-history-of-biotechnology 2020-10-20T15:11:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-good-news-today-and-more-is-expected 2026-04-18T17:29:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/covid-19-vaccines-from-pfizer-biontech-and-moderna 2020-10-16T11:13:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cytokinetics-product-omecamtiv-mecarbil-for-heart-failure-with-reduced-ejection-fraction 2026-06-09T00:57:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-doses-the-first-patient-with-cdx-0159-for-csu 2026-04-26T00:46:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/filgotinib-has-become-great-news-for-gilead-sciences-and-galapagos-nv 2020-10-13T10:04:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-adds-an-immuno-oncology-pioneer-to-its-sab 2020-10-08T13:13:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-acquisition-of-myokardia-see-also-vir-and-gsk 2026-06-25T14:54:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-news-see-also-sars-cov-2-virus-vs-the-president-of-the-us 2020-10-06T11:57:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-lifted-the-clinical-hold-on-solid-biosciences-ignite-dmd 2020-10-01T12:32:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/enlivex-therapeutics-product-allocetratm-saves-severe-critical-covid-19-patients 2020-10-01T11:04:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-moderna-and-sorrento-therapeutics-all-have-news 2026-05-01T08:44:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sorrento-therapeutics-releases-preclinical-data-from-sti-1499-and-sti-2020 2026-05-02T03:43:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/johnson-johnson-launches-a-large-scale-phase-3-trial-of-its-covid-19-vaccine 2020-09-29T12:20:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-442-the-whole-world-against-the-sars-cov-2-virus 2026-04-26T10:57:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/revolution-medicines-inc-has-revolutionary-hews 2020-09-25T12:10:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-kras-g12c-inhibitor-product-sotorasib-has-thrilling-results 2026-06-16T20:54:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-and-vertex-pharmaceuticals-product-ctx001-for-severe-scd-was-granted-prime-designation-by-ema 2020-09-22T13:53:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/eli-lilly-neutralizing-antibody-ly-cov555-promises-a-reduction-in-covid-19-patients-hospitalization 2026-06-16T09:53:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seattle-genetics-two-new-oncology-collaborations-with-merck 2026-05-12T11:11:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-promising-and-encouraging-results-of-its-alzheimers-product-sumifilam 2020-09-14T12:21:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-could-acquire-immunomedics-at-20-billion 2020-09-12T17:35:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/agenus-stock-rallied-yesterday-results-are-upcoming-at-esmo 2020-09-21T17:56:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/thermo-fisher-will-manufacture-the-inovio-covid-19-vaccine-candidate 2020-09-09T11:01:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-announced-news-from-its-phase-1-2-study-of-com701 2020-09-08T10:38:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-and-glaxosmithkline-covid-19-vaccines-are-advancing-in-clinical-trial 2020-09-03T13:29:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-u-s-cdc-tells-the-50-states-to-prepare-for-covid-19-vaccines 2026-05-19T21:24:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/agenus-could-it-be-a-resurrection-see-also-prohost-performing-stocks 2026-04-29T00:04:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-inc-stock-is-tanking-after-rallying-for-what-reason 2020-09-03T10:04:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-the-time-has-come-for-rhythm-pharmaceuticals-to-outperform 2026-06-21T03:29:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-encouraging-news-see-also-translate-bio-and-sanofi-news 2020-08-27T11:41:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-announces-submission-of-snda-to-us-fda-for-cabozantinib-in-combination-with-nivolumab-for-advanced-rcc 2026-04-18T21:10:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/kazia-therapeutics-ltd-product-paxalisib-beat-temozolomide 2020-08-28T11:41:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/whats-going-on-with-gene-therapy 2026-06-13T07:30:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/us-fdas-complete-response-letter-creating-investment-opportunities 2021-08-31T15:00:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-an-fda-clr-will-not-stop-this-firm-from-rallying 2020-08-19T13:12:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-royal-reception-by-investors-for-curevac-see-also-bristol-myers 2020-08-17T15:32:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-announcement-from-sorrento-therapeutics 2026-05-01T05:01:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/monopar-therapeutics-plan-for-a-test-to-predict-covid-19-complications 2026-04-20T05:40:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/intellia-therapeutics-realizing-the-dream-of-curing-devastating-diseases 2020-08-11T10:30:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seres-therapeutics-product-ser-109-meets-trial-endpoint 2020-08-20T16:06:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alterity-therapeutics-treating-neurodegenerative-diseases 2020-08-05T09:59:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-positive-one-year-data-for-rgx-314-for-wet-amd 2020-08-04T10:55:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-why-we-think-it-is-a-stock-worth-keeping 2020-08-29T07:36:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-good-news-about-the-firms-covid-19-vaccine 2020-07-30T19:30:12.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/edesa-biotech-stock-price-soared-the-question-now-is-will-it-continue-to-rise 2020-07-30T11:27:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-news-see-also-regeneron-antibody-cocktail 2020-07-29T15:36:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-car-t-cell-product-tecartus-gets-fda-approval 2020-07-27T12:36:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/tcr2-therapeutics-encouraging-oncology-results 2020-07-27T10:33:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/could-arbutus-biopharma-patent-harm-moderna 2020-09-28T07:54:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/jazz-pharmaceuticals-a-new-fda-approval-for-narcolepsy 2020-07-24T12:01:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ibio-the-small-firm-whose-stock-soared-in-yesterdays-market 2026-04-23T19:45:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-a-new-gene-therapy-series-starts-today 2020-07-16T13:22:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inmune-bio-a-novel-approach-towards-treating-alzheimers-disease 2020-07-14T09:32:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pfizer-and-biontech-a-lot-more-to-say-about-the-covid-19-vaccines 2020-07-13T11:21:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-stock-is-skyrocketing 2020-07-08T15:52:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/corvus-pharmaceuticals-a-novel-immunotherapy-approach-for-covid-19 2026-04-17T15:48:34.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-441-are-we-saying-goodbye-to-common-sense 2020-09-28T07:51:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-a-cautious-decision-by-prohost-biotech 2020-07-01T14:43:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/akero-therapeutics-efruxifermin-demonstrates-strong-results-in-nash 2020-07-01T14:35:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-we-are-not-yet-in-bizarro-world 2020-06-30T11:25:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-letter-to-prohost-biotech-readers-and-subscribers 2026-04-26T20:58:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-novel-coronavirus-vaccines-developing-firms-evaluations 2026-05-19T21:39:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-received-71-million-in-funding-from-the-u-s-department-of-defense 2020-06-23T10:04:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-time-has-come-for-agenus-to-excel-see-also-evoke-pharma 2026-04-30T22:55:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/good-news-for-four-companies-jazz-celldex-inventiva-iventiva 2026-07-01T22:42:24.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-and-vertex-have-encouraging-news 2026-04-30T11:11:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/celldex-therapeutics-the-beginning-of-the-firms-resurrection 2026-04-26T02:31:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-stock-soared-today-on-good-news 2020-06-11T14:09:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-mrna-1273-vaccine-for-novel-coronavirus 2020-06-23T10:28:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/curis-inc-has-the-time-come-to-flex-its-muscles 2026-05-09T02:06:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-potential-merger-between-astrazeneca-plc-and-gilead-sciences 2020-06-08T12:12:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/myovant-sciences-recent-news-is-good-for-prostate-cancer-patients 2020-06-23T10:30:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-predictive-computational-discovery-technology 2020-06-23T10:31:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sonoma-pharmaceuticals-and-adaptimmune-stock-prices-skyrocketed 2026-06-16T04:50:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-questions-answers-and-covid-19-vaccines 2026-06-20T14:49:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nektar-therapeutics-product-bempeg-nktr-214-in-combination-nivolumab 2020-05-22T12:17:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/navidea-biopharmaceuticals-why-this-small-firms-stock-skyrocketed 2026-05-11T23:26:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-and-galapagos-nv-good-news-from-filgotinib-in-uc 2020-05-21T09:05:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-ino-4800-vaccine-against-the-novel-coronavirus 2026-04-23T08:33:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-inc-a-public-offering-of-17600000-shares-at-76-per-share 2020-05-19T08:50:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-positive-news-for-its-mrna-1273-vaccine-against-covid-19 2020-05-18T09:11:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sorrento-therapeutics-sti-1499-an-encouraging-anti-sars-cov-2-antibody 2020-08-28T16:05:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bristol-myers-squibb-and-bluebird-bio-product-ide-cel-bb2121-and-the-fda-refusal-letter-what-do-we-expect 2020-05-13T16:26:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novavax-a-profile-and-a-comment-more-covid-19-vaccines-needed 2020-06-23T10:35:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novavax-cymabay-therapeutics-and-sanofi-sa-impacting-news 2026-05-14T23:35:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-440-novel-coronavirus-the-therapeutics 2020-09-28T07:51:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/pluristem-therapeutics-the-fda-cleared-phase-2-study-of-its-plx-cells 2020-06-23T10:41:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-cleared-by-fda-for-coronavirus-vaccine-to-phase-2-trial 2020-05-07T08:20:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alexion-pharmaceuticals-to-acquire-portola-at-18-per-share 2026-05-11T14:54:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/applied-dna-sciences-and-takis-biotech-joint-press-release 2020-06-23T10:43:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-the-time-has-come-for-cytomx-to-grow-and-thrive 2026-06-15T17:59:00.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-developing-a-vaccine-against-the-novel-coronavirus 2020-04-28T11:33:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/sanofi-and-regeneron-results-from-libtayo-trial-for-advanced-nsclc 2020-04-27T11:21:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/be-careful-not-to-underestimate-theravance-biopharma 2026-04-20T04:20:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/be-careful-not-to-underestimate-halozyme-and-ptc-therapeutics 2026-05-22T18:28:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-a-new-important-patent-from-europe-and-much-more 2020-04-22T11:22:27.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-world-focus-is-on-the-novel-coronavirus-treatments-and-vaccines 2022-04-02T09:11:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-is-rallying-today-from-checkmate-9er-results 2020-04-21T06:08:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-gilead-sciences-and-moderna-incs-stocks-rallied-today 2020-04-17T06:11:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-a-small-firm-with-giant-technological-capabilities 2020-04-22T09:57:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/learning-more-about-moderna-therapeutics-virtual-vaccine-day 2020-04-14T15:56:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/inovio-pharmaceuticals-an-evaluation-of-biotech-firms-part-4 2026-06-22T03:56:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novavax-has-identified-an-ideal-coronavirus-vaccine-candidate 2026-04-30T04:48:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/encouraging-news-about-covid-19-outbreak-see-also-gilead-sciences 2020-04-08T10:55:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-time-has-come-for-us-to-present-fate-therapeutics 2026-06-29T14:48:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/urogen-pharma-an-introduction-and-discussion-of-its-pipeline-of-products 2020-06-23T11:22:42.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-and-regeneron-two-companies-coronavirus-will-fail-to-disrupt 2020-03-31T13:35:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-we-are-still-optimistic-see-also-inovio-good-news 2020-03-27T13:18:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/good-news-for-exelixis-and-for-japanese-renal-cell-carcinoma-patients 2020-03-25T11:16:33.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/stars-before-coronavirus-outbreak-and-those-firms-treating-covid-19 2026-04-29T21:12:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/its-all-about-coronavirus-covid-19-and-possible-treaments 2026-05-01T15:29:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/market-chaos-see-also-modernas-human-trial-began-today 2020-06-23T11:25:30.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-market-rebounding-that-left-important-biotechnology-firms-behind 2021-01-12T11:47:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/stock-market-frustration-volatility-and-chaos-see-also-moderna-gilead 2020-06-23T11:32:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen-the-small-stock-that-refused-to-kneel 2020-03-09T15:33:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nanoviricides-and-other-firms-working-on-treatments-for-covid-19 2020-03-09T06:27:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/covid-19-the-fight-see-also-stocks-gains-after-market-rebounding 2026-05-12T07:29:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-market-is-rebounding-see-also-biotech-firms-inspiring-news 2020-06-23T11:41:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-to-acquire-forty-seven-at-95-50-a-share-in-cash 2020-03-04T11:32:29.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/more-about-moderna-giliad-forty-seven-and-covid-19 2020-02-28T14:51:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/how-coronavirus-and-covid-19-are-affecting-the-stock-market 2020-06-23T11:45:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-and-moderna-are-both-outperforming-today 2020-02-25T15:13:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-and-moderna-stocks-expected-to-outperform-in-todays-market 2020-02-24T10:38:11.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-439-the-coronavirus-outbreak-covid-19 2026-06-14T00:51:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/crispr-therapeutics-and-sisters 2020-02-17T09:24:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-has-good-news-from-alzheimers-disease-trial 2026-04-11T10:48:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-moderna-therapeutics-stock-is-down-today-after-soaring 2020-02-24T10:37:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-has-good-news-for-metastatic-castration-resistant-prostate-cancer 2020-06-23T12:20:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-regeneron-pharmaceuticals-stock-is-soaring 2020-02-11T14:51:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/a-synopsis-of-some-biotech-companies-events 2026-06-28T03:04:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/could-nektar-therapeutics-product-nktr-214-bempeg-become-a-blockbuster 2020-02-05T10:21:39.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/in-the-market-that-seems-to-soar-today-we-are-watching-several-biotech-stocks 2026-06-28T03:04:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-gilead-stock-is-up-4-see-also-prophylactic-vaccines-for-2019-nc0v 2020-06-23T11:55:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-beats-expectations-in-2019-and-promises-a-bright-future 2020-06-23T11:57:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-moderna-therapeutics-and-other-biotech-stocks-posted-gains-in-a-bad-market-day 2020-02-24T10:42:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/compugen 2020-06-23T12:02:01.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-ema-validates-the-gilead-application-for-a-car-t-product-for-mcl 2020-01-29T12:31:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-moderna-stock-is-boosted-in-todays-bad-stock-market-day 2020-02-24T10:43:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-evaluation-of-biotech-firms-part-3-incyte 2026-05-20T05:48:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-moderna-stock-is-rallying-see-also-in-the-news-coronavirus 2020-01-22T14:36:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/forty-seven-continues-to-outperform 2020-06-23T12:04:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/midday-thursday-january-16-outperforming-prohost-picks 2020-01-16T12:46:46.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nektar-is-still-a-favorite-even-after-the-fdas-no-vote-for-oxycodegal 2020-01-15T11:42:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-evaluation-of-biotech-firms-part-2-vertex-pharmaceuticals 2020-01-23T15:59:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-xbiotech-interesting-news-that-rallied-its-stock 2020-01-14T12:27:19.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-beginning-of-a-nektar-therapeutics-outperformance 2020-01-11T10:47:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-trial-data-for-mrna-1647-is-important-and-significant 2020-01-10T13:40:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-evaluation-of-biotech-firms-part-1-vertex-pharmaceuticals 2020-01-23T15:57:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-good-news-prohost-comprehensive-essay-with-informative-real-stories-about-biotech-stocks 2020-01-07T14:26:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-438-the-end-of-the-year-issue-2019 2026-05-04T11:06:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/can-cassava-sciences-product-pti-125-beat-alzheimers-disease 2021-11-08T12:10:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/cassava-sciences-more-positive-news-in-alzheimers-disease 2021-11-08T12:05:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-48-holiday-edition 2026-05-01T08:59:18.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/more-from-the-prohost-portfolio 2021-11-08T12:14:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-promising-results-from-rgx-121-gene-therapy-for-mps-ii 2019-12-19T13:44:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amylyx-pharmaceuticals-clinical-trial-results-demonstrate-statistically-significant-treatment-benefit-in-lou-gehrigs-disease-patients 2019-12-17T12:56:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amarin-the-fda-approves-vascepa-for-lowering-cardiovascular-risk 2019-12-16T14:21:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-and-genentech-roche-combination-has-positive-results 2019-12-13T12:00:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ionis-and-alnylam-secured-their-future-prosperity 2019-12-14T08:18:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nektar-at-the-61st-american-society-of-hematology-ash-meeting 2026-06-28T03:04:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gileads-car-t-product-yescarta-demonstrates-positive-survival-results 2026-06-20T23:20:31.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-prohost-portfolio-table-1-highest-revenues-incomes-dividends 2019-12-07T11:57:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/let-the-market-plummet-but-not-prohost-picked-stocks 2026-06-26T21:40:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novartis-to-acquire-the-medicines-company-at-85-a-share 2019-11-25T08:40:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-437-an-all-time-high-market-the-prohost-portfolio 2026-05-30T16:55:57.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alnylam-its-second-rnai-therapy-approval-boosted-savvy-investors-trust 2019-11-22T11:15:56.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-vertex-and-crispr-rallied-today 2019-11-23T10:21:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/ptc-therapeutics-product-risdiplam-met-trial-endpoints-for-sma 2019-11-14T10:33:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-a-successful-treatment-for-alport-syndrome 2019-11-13T10:42:08.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/another-approval-from-canada-for-exelixis-product-cabometyx 2019-11-12T13:00:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/another-approval-for-celgene-and-the-first-for-acceleron 2026-06-16T09:29:13.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-47-what-a-week-for-biotechnology 2026-06-13T01:23:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-and-daiichi-sankyo-preventing-and-treating-diabetic-nephropathy 2026-05-04T20:03:15.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-bad-news-that-might-save-the-life-of-halozyme-therapeutics 2026-05-18T11:54:50.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/karyopharm-therapeutics-a-star-is-born-other-outperforming-stocks-too 2026-06-30T02:30:54.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-fda-approves-compugens-ind-for-its-oncology-product-com902 2019-11-04T12:06:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-the-quarterly-financial-results 2026-06-30T02:45:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/iveric-bio-stock-doubled-and-continues-to-outperform 2026-06-30T14:59:04.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/when-negative-reactions-to-biotech-news-mislead-regenxbio-selloff 2019-10-31T10:24:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-what-was-seen-and-what-was-ignored 2022-04-02T09:14:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/spring-bank-pharmaceuticals-inarigivir-and-gilead-sciences-vemlidy-for-hbv 2019-10-24T06:44:06.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-week-in-review-43-this-past-week-for-biotechnology 2026-06-26T07:01:10.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-seattle-genetics-gained-1329-currently-trading-at-100-69 2026-05-13T00:27:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bayer-advancing-ionis-fxi-lrx-see-also-hepion-pharmaceuticals 2026-07-01T06:05:23.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/hepion-pharmaceuticals-product-crv431-decreases-fibrosis-and-tumor-development-in-chronic-liver-disease-models 2020-06-23T12:13:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/reata-pharmaceuticals-omaveloxolone-met-trial-primary-endpoints-for-fa 2019-11-07T15:34:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-is-rebounding-asee-also-crispr-and-ksq-therapeutics 2019-10-24T06:50:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-phase-i-iia-trial-results-from-gene-therapy-product-rgx-314 2020-06-23T12:19:49.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/novartis-plenty-of-good-news-see-also-topics-for-a-week-in-review 2019-10-11T07:13:37.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/more-news-for-nektar-therapeutics-nktr-358 2019-10-08T15:08:38.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/during-the-departed-week-the-week-in-review-42 2026-06-04T23:19:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/prohost-letter-436-what-are-we-experiencing-now 2019-10-16T14:28:55.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seattle-genetics-product-tucatinib-beats-agressive-colorectal-cancer-the-stocks-price-soars 2026-06-23T23:06:20.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/enanta-product-epd-305-has-promising-results-for-the-treatment-nash 2026-06-16T11:34:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/could-incytes-ruxolitinib-cream-effectively-treat-vitiligo 2026-05-20T03:40:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-medicines-company-orion-trial-improving-ascvd 2019-09-26T10:50:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/news-from-nektar-bristol-myers-and-merck-see-also-biotechs-bizarre 2026-06-28T03:04:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-value-of-the-biotech-companies-continued 2026-06-20T21:29:45.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/bluebird-bio-investigational-gene-therapy-demonstrating-promising 2019-09-20T11:32:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/atara-biotherapeutics-ata188-for-ebv-infecting-b-cells-causing-ms 2019-09-17T11:05:47.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/alder-eptinezumab-for-migraine-lundbeck-to-acquire-alder-stock-gained 2026-04-18T04:32:05.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-therapeutics-a-big-day-is-filled-with-good-news 2019-09-13T15:05:41.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-and-clearside-biomedical-agreement-and-more 2019-09-11T13:04:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgens-oncology-product-amg-510-for-kras-g12c-mutated-cancers 2026-04-27T09:35:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/vertex-in-pursuit-of-cures-acquiring-semma-therapeutics 2019-09-04T10:41:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/outperforming-biotechs-in-a-bad-market-day-mdco-cdtx 2019-09-17T11:59:53.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gene-therapy-and-other-treatments-that-work-at-the-genetic-level 2026-06-18T12:40:40.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-medicines-company-has-agreeable-news 2026-05-27T18:38:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/amgen-to-acquire-celgenes-product-otezia-at-13-4-billion 2026-06-13T00:36:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/astrazeneca-and-vertex-both-have-good-news 2019-08-22T06:33:52.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/moderna-investigational-zika-vaccine-granted-fda-fast-track-designation 2020-06-23T12:24:07.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-bizarre-market 2026-05-26T15:21:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-akari-therapeutics-sock-price-rallied-today 2026-05-11T05:21:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-product-regn-eb3-is-saving-lives-from-ebola 2019-08-13T14:05:35.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regeneron-press-release-about-product-regn-eb3 2020-06-23T12:29:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-value-of-the-biotech-companies-prohost-letter-434 2020-03-05T15:17:28.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-amgens-stock-is-up-over-11-today-august-9-2019 2019-08-11T13:16:59.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/court-upholds-validity-of-amgen-claims-regarding-enbrel-the-companys-press-realease 2020-06-23T12:36:32.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nektars-story-has-nothing-to-do-with-the-efficacy-or-value-of-nktr-214 2019-08-11T13:03:02.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/nektar-therapeutics-q2-results-for-2019-press-release 2020-06-23T12:44:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/unveiled-good-news-about-prohost-picked-biotech-stocks 2026-05-20T03:54:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/rhythm-pharmaceuticals-has-good-news-see-also-the-novartis-news 2026-06-26T14:29:43.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/what-did-we-learn-from-yesterdays-and-todays-stocks-moves 2019-08-06T11:46:17.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/about-impacting-news 2020-06-23T12:46:14.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/an-important-statement-to-prohost-readers 2019-08-05T09:16:48.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/the-nektar-good-news-cannot-be-hidden-any-longer 2026-04-28T18:56:21.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/regenxbio-has-good-news-from-its-licensing-agreement-with-pfizer 2019-08-01T09:09:26.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/why-we-decided-not-to-abandon-the-amgen-and-illumina-band-wagons 2019-08-01T09:34:16.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-sciences-activities-are-exceeding-all-time-high 2026-06-25T04:27:58.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/halozyme-and-argenx-most-recent-news 2026-05-18T14:39:36.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/seattle-genetics-deserves-its-stock-rally 2026-05-12T23:12:03.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/takeda-and-cira-icart-toward-improving-on-car-t-effectiveness 2026-05-01T09:50:44.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/gilead-and-galapagos-agreement-is-a-big-win-for-both-firms-and 2019-07-15T12:17:51.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/exelixis-encouraging-results-from-cabozantinib-trial 2019-07-15T09:21:22.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/illumina-stockdropped-following-a-preliminary-revenue-announcement 2019-07-12T09:51:09.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/article/libtayo-from-regeneron-is-unique-and-expected-to-become-a-best-seller 2019-07-09T15:06:25.000Z weekly 0.8 https://prohostf.smartnoticeboard.io/category/impacting-news weekly 0.6 https://prohostf.smartnoticeboard.io/category/news-comments weekly 0.6 https://prohostf.smartnoticeboard.io/category/trick-or-trade weekly 0.6 https://prohostf.smartnoticeboard.io/category/todays-highlights weekly 0.6 https://prohostf.smartnoticeboard.io/category/prohost-letters weekly 0.6 https://prohostf.smartnoticeboard.io/tag/23andme-holding-co-me weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abbott-laboratories-abt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abbvie-inc-abbv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abcellera weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abeona-therapeutics-abeo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abiomed-inc-abmd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ablynx-ablx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/abvitro-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acadia-acad weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acceleron-pharma-xlrn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acelrx-acrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acelrx-pharmaceuticals-acrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/achaogen-inc-akao weekly 0.4 https://prohostf.smartnoticeboard.io/tag/achillion-pharmaceuticals-achn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aciex-therapeutics-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acorda-therapeutics-inc-acor weekly 0.4 https://prohostf.smartnoticeboard.io/tag/acumen-pharmaceuticals-abos weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adaptimmune-therapeutics-adap weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adaptive-biotechnologies weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adc-therapeutics-adct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adeona-aen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adimab-llc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aduro-biotech-inc-adro weekly 0.4 https://prohostf.smartnoticeboard.io/tag/advanced-micro-devices-amd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/advaxis-adxs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adventrix-anx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/adverum-biotechnologies-advm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aegerion-aegr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aerie-pharmaceuticals-aeri weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aeterna-zentaris-aezs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/affymax-affy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/affymertix-affx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agentus-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agenus-agen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agex-therapeutics-age weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agilent-technologies-a weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agilis-biotherapeutics-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/agios-pharmaceuticals-agio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aim-immunotech-aim weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aimmune-therapeutics-aimt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akari-therapeutics-aktx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akashi-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akcea-therapeutics-akca weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akebia-therapeutics-inc-akba weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akero-therapeutics-akro weekly 0.4 https://prohostf.smartnoticeboard.io/tag/akous-inc-a-wholly-owned-subsidiary-of-eli-lilly-company weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alcobra-ltd-adhd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alder-biopharmaceuticals-aldr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alexion-pharmaceuticals-alxn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aligos-therapeutics-algs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alimera-sciences-alim weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alkermes-alks weekly 0.4 https://prohostf.smartnoticeboard.io/tag/allergan-plc-agn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/allogene-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/allogene-therapeutics-allo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alnylam-pharmaceuticals-alny weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alpine-immune-sciences-alpn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/alterity-therapeutics-athe weekly 0.4 https://prohostf.smartnoticeboard.io/tag/altimmune-alt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amag-pharmaceuticals-amag weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amarin-amrn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amarin-corporation-amrn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/american-society-of-clinical-oncology-asco weekly 0.4 https://prohostf.smartnoticeboard.io/tag/american-society-of-hematology-ash weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amgen-amgn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amicus-therapeutics-fold weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amylin-amln weekly 0.4 https://prohostf.smartnoticeboard.io/tag/amylyx-pharmaceuticals-amlx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/anacor-pharmaceuticals-anac weekly 0.4 https://prohostf.smartnoticeboard.io/tag/anadys-ands weekly 0.4 https://prohostf.smartnoticeboard.io/tag/anavex-life-sciences-avxl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/anika-therapeutics-anik weekly 0.4 https://prohostf.smartnoticeboard.io/tag/anixa-biosciences-anix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/annovis-bio-inc-anvs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/antares-phama-ais weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aop-orphan weekly 0.4 https://prohostf.smartnoticeboard.io/tag/apellis-pharmaceuticals-apls weekly 0.4 https://prohostf.smartnoticeboard.io/tag/apple-inc-aapl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/applied-dna-sciences-apdn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aptevo-therapeutics-inc-apvo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arbor-biotechnologies weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arbutus-biopharma-abus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arca-biopharma-inc-abio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arcturus-therapeutics-holdings-arct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arcus-biosciences-rcus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ardelyx-ardx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arena-pharmaceuticals-arna weekly 0.4 https://prohostf.smartnoticeboard.io/tag/argenx-argx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/argenx-se-argx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/argos-therapeutics-args weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aria-diagnostics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ariad-pharmaceuticals-aria weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ariosa-diagnostics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arqule-inc-arql weekly 0.4 https://prohostf.smartnoticeboard.io/tag/array-biopharma-arry weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arrowhead-pharmaceuticals-arwr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ars-pharmaceuticals-spry weekly 0.4 https://prohostf.smartnoticeboard.io/tag/arvinas weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aslan-pharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aslan-pharmaceuticals-asln weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aspen-neuroscience weekly 0.4 https://prohostf.smartnoticeboard.io/tag/astellas-pharma-alpmy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/astrazeneca-plc-azn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/astria-therapeutics-atxs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/atara-biotherapeutics-atra weekly 0.4 https://prohostf.smartnoticeboard.io/tag/atea-pharmaceuticals-avir weekly 0.4 https://prohostf.smartnoticeboard.io/tag/atossa-genetics-atos weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aurigene-discovery-technologies-limited weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aurinia-pharmaceuticals-auph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/auris-medical-holding-ltd-ears weekly 0.4 https://prohostf.smartnoticeboard.io/tag/auspex-pharmaceuticals-inc-aspx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/autonomix-medical-amix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/auxilium-pharmaceuticals-auxl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/avanir-pharmaceuticals-avnr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/aveo-pharmaceuticals-inc-aveo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/avexis-inc-avxs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/avista-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/axovant-axgt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/axsome-therapeutics-axsm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/basilea-pharmaceutica-bpmuf weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bausch-health-companies-bhc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/baxalta-bxlt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/baxter-international-inc-bax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bayer-bayry weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bayer-ag-bayn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/be-one-medicines-onc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/beam-therapeutics-beam weekly 0.4 https://prohostf.smartnoticeboard.io/tag/beam-therapeutics-inc-celgene-celg weekly 0.4 https://prohostf.smartnoticeboard.io/tag/beckman-coulter weekly 0.4 https://prohostf.smartnoticeboard.io/tag/beigene-ltd-bgne weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bellicum-pharmaceuticals-inc-blcm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/benlysta-belimumab weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bio-techne-corporation-tech weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bioartic-ab-bioa-b weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biocardia-inc-bcda weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biocryst-pharmaceuticals-bcrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biodelivery-sciences-international-bdsi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biogen-inc-biib weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bioinvent-international-ab-binv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biolinerx-ltd-blrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biomarin-pharmaceutical-bmrn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biontech-bntx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biontech-se-bntx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biosig-technologies-bsgm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biostem-technologies-bsem weekly 0.4 https://prohostf.smartnoticeboard.io/tag/biotime-inc-btx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/blackstone-life-sciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bluebird-bio-inc-blue weekly 0.4 https://prohostf.smartnoticeboard.io/tag/blueprint-medicines-bpmc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bluerock-therapeutics-lp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/boehringer-ingelheim weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bostwick-laboratories weekly 0.4 https://prohostf.smartnoticeboard.io/tag/brainstorm-cell-therapeuctics-inc-bcli weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bridgebio-pharma-bbio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/brii-biosciences-brii-bio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/bristol-myers-squibb-bmy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/broadcom-inc-avgo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/calithera-biosciences-cala weekly 0.4 https://prohostf.smartnoticeboard.io/tag/can-fite-biopharma-canf weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cancer-research-uk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/car-nk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/car-t weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cara-therapeutics-cara weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cardior-pharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cardium-therapeutics-cxm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/caribou-biosciences-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/carlisle-companies-inc-csl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/carsgen-therapeutics-holdings-limited weekly 0.4 https://prohostf.smartnoticeboard.io/tag/casebia-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/casebla-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/casi-pharmaceuticals-inc-casi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/casma-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cassava-sciences-sava weekly 0.4 https://prohostf.smartnoticeboard.io/tag/catabasis-pharmaceuticals-inc-catb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celator-pharmaceuticals-cpxx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celgene-celg weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cell-designs-labs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cellceutix-corporation-ctix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celldex-therapeutics-cldx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cellectis-clls weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cellex-cell-professionals-gmbh-cellex weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celltrans-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celmatix-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celsion-corporation-clsn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celularity-inc-celu weekly 0.4 https://prohostf.smartnoticeboard.io/tag/celyad-cyad weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cempra-cemp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/center-for-ips-cell-research-and-application-cira weekly 0.4 https://prohostf.smartnoticeboard.io/tag/centessa-pharmaceuticals-cnta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/century-therapeutics-ipsc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cerevel-therapeutics-cere weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cerulean-pharma-ceru weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cetus-capital-llc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/checkmate-pharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/checkpoint-therapeutics-ckpt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/chelsea-therapeutics-chtp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/chemocentryx-ccxi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/chemocentryx-inc-ccxi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/childrens-hospital-of-philadelphia-chop weekly 0.4 https://prohostf.smartnoticeboard.io/tag/chimerix-inc-cmrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/chiron-investment-management weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cidara-therapeutics-cdtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/clearside-biomedical-clsd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/clearside-biomedical-inc-clsd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/clene-inc-clnn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/clovis-oncology-clvs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cogent weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cogent-biosciences-cogt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cognition-therapeutics-cgtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cold-spring-harbor-laboratory-cshl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/complete-genomics-gnom weekly 0.4 https://prohostf.smartnoticeboard.io/tag/compugen-cgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/concert-pharmaceuticals-cnce weekly 0.4 https://prohostf.smartnoticeboard.io/tag/confluent-surgical-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/corcept-therapeutics-cort weekly 0.4 https://prohostf.smartnoticeboard.io/tag/corium-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/corner-therapeutics-crtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/corvus-pharmaceuticals-crvs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/coya-therapeutics-inc-coya weekly 0.4 https://prohostf.smartnoticeboard.io/tag/credit-suisse weekly 0.4 https://prohostf.smartnoticeboard.io/tag/crinetics-pharmaceuticals-crnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/crispr-therapeutics-crsp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/csl-limited-cslax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cspc-pharmaceutical-group-cspc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cti-biopharma-corp-ctic weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cubist-pharmaceuticals-cbst weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cullinan-oncology-cgem weekly 0.4 https://prohostf.smartnoticeboard.io/tag/curevac-cvac weekly 0.4 https://prohostf.smartnoticeboard.io/tag/curis-cris weekly 0.4 https://prohostf.smartnoticeboard.io/tag/curis-inc-cris weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cyclacel-pharmaceuticals-cycc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cymabay-therapeutics-cbay weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cypher-genomics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cytokinetics-cytk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cytomx-therapeutics-inc-ctmx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cytori-therapeutics-cytx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/cytovia-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/daiichi-sankyo-dsnky weekly 0.4 https://prohostf.smartnoticeboard.io/tag/daiichi-sankyo-co-ltd-dskyf weekly 0.4 https://prohostf.smartnoticeboard.io/tag/delcath-dcth weekly 0.4 https://prohostf.smartnoticeboard.io/tag/delmar-pharmaceuticals-dmpi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/denali-therapeutics-inc-dnli weekly 0.4 https://prohostf.smartnoticeboard.io/tag/dendreon-dndn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/dermira-inc-derm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/discovery-laboratories-dsco weekly 0.4 https://prohostf.smartnoticeboard.io/tag/dyax-corp-dyax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/dynavax-technologies-dvax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ebola weekly 0.4 https://prohostf.smartnoticeboard.io/tag/edesa-biotech-edsa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/editas-medicine-inc-edit weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eisai-co-ltd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eisai-pharmaceutical-co-esaly weekly 0.4 https://prohostf.smartnoticeboard.io/tag/elan-eln weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eledon-pharmaceuticals-eldn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eli-lilly-lly weekly 0.4 https://prohostf.smartnoticeboard.io/tag/emd-serono weekly 0.4 https://prohostf.smartnoticeboard.io/tag/emd-serono-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/emergent-biosolutions-ebs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/enanta-pharmaceuticals-enta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/endo-international-plc-endp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/endocyte-ecyt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/endogena-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/endometrial-cancer weekly 0.4 https://prohostf.smartnoticeboard.io/tag/enlivex-enlv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/enlivex-therapeutics-enlv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/envivo-pharmaceuticals-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/epizyme-inc-epzm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/erasca-inc-eras weekly 0.4 https://prohostf.smartnoticeboard.io/tag/esperion-therapeutics-espr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/european-association-for-the-study-of-the-liver-easl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eusa-pharma weekly 0.4 https://prohostf.smartnoticeboard.io/tag/everest-medicines weekly 0.4 https://prohostf.smartnoticeboard.io/tag/evoke-pharma-evok weekly 0.4 https://prohostf.smartnoticeboard.io/tag/evotec-se-evo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/exact-sciences-exas weekly 0.4 https://prohostf.smartnoticeboard.io/tag/excision-biotherapeutics-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/exelixis-exel weekly 0.4 https://prohostf.smartnoticeboard.io/tag/exonics-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/exxon-mobil weekly 0.4 https://prohostf.smartnoticeboard.io/tag/eyepoint-pharmaceuticals-eypt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/fate-therapeutics-fate weekly 0.4 https://prohostf.smartnoticeboard.io/tag/five-prime-therapeutics-fprx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/fluent-biosciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/forty-seven-inc-ftsv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/foundation-medicine-fmi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/fujirebio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gain-therapeutics-inc-ganx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/galapagos-nv-glpg weekly 0.4 https://prohostf.smartnoticeboard.io/tag/galderma-galdsw weekly 0.4 https://prohostf.smartnoticeboard.io/tag/galena-biopharma-gale weekly 0.4 https://prohostf.smartnoticeboard.io/tag/galenea-corporation weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gemoab-gmbh weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genelux-corporation weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genentech weekly 0.4 https://prohostf.smartnoticeboard.io/tag/generex-biotech-corp-gnbt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genesis-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genethon weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genevant-sciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genmab-gmab weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genomedx-biosciences-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/genomic-health-inc-ghdx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/geron-corporation-gern weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gilead-sciences-gild weekly 0.4 https://prohostf.smartnoticeboard.io/tag/global-blood-therapeutics-gbt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/glycomimetics-inc-glyc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/grail-inc-gral weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gritstone-oncology-grts weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gsk-plc-gsk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/guardant-health-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/gw-pharmaceuticals-gwph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/halozyme-therapeutics-halo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/harmony-biosciences-hrmy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hemishperx-biopharma-inc-heb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hepion-pharmaceuticals-hepa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/herceptin weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hercules-capital-htgc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/heron-therapeutics-hrtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/histogenics-corp-hsgx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hologic-inc-holx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/horizon-pharmaceuticals-hznp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hoth-therapeutics-hoth weekly 0.4 https://prohostf.smartnoticeboard.io/tag/human-genome-sciences-hgsi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/human-longevity-hli weekly 0.4 https://prohostf.smartnoticeboard.io/tag/humanigen-inc-hgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/hutchmed-ltd-hcm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/i-mab-biopharma-imab weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ibiopharma-inc-ibio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ibm-watson-health weekly 0.4 https://prohostf.smartnoticeboard.io/tag/iconic-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/idenix-idix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/idera-pharmaceuticals-idra weekly 0.4 https://prohostf.smartnoticeboard.io/tag/idrx-biopharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ifm-therapeutics-llc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ifm-tre weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ignyta-inc-rxdx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/illumina-ilmn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immune-design-imdz weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunity-bio-ibrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunocellular-therapeutics-ltd-imuc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunogen-imgn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunome-inc-imnm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunomedics-immu weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunovant-inc-imvt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immunovent-imvt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/immutep-ltd-immp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/impel-neuropharma-impl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/incyte-incy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/infinity-pharmaceuticals-infi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inflarx-biopharmaceutical-ifrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inhibrx-inc-inbx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inmune-bio-inmb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inmune-bio-inc-inmb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/innate-pharma-sa-ipha weekly 0.4 https://prohostf.smartnoticeboard.io/tag/innovent-biologics-ivbxf weekly 0.4 https://prohostf.smartnoticeboard.io/tag/innoviva-inva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inovio-ino weekly 0.4 https://prohostf.smartnoticeboard.io/tag/insightec-ltd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/insilico-medicine weekly 0.4 https://prohostf.smartnoticeboard.io/tag/insitro weekly 0.4 https://prohostf.smartnoticeboard.io/tag/insmed-inc-insm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/insmed-incorporated-insm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/integrated-biotherapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intellia-therapeutics-ntla weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intelligent-bio-systems-inc-ibs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intercept-pharmaceuticals-icpt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intermune-inc-itmn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intra-cellular-therapies-itci weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intrabio-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/intrexon-xon weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/inventiva-euronext-iva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/invivyd-inc-ivvd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ionis-pharmaceuticals-inc-ions weekly 0.4 https://prohostf.smartnoticeboard.io/tag/iovance-biotherapeutics-iova weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ipsen-pharma-ipn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/italfarmaco weekly 0.4 https://prohostf.smartnoticeboard.io/tag/iterum-therapeutics-itrm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/iveric-bio-isee weekly 0.4 https://prohostf.smartnoticeboard.io/tag/janssen-alzheimer-immunotherpay weekly 0.4 https://prohostf.smartnoticeboard.io/tag/janssen-pharmaceuticals-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/janus-kinase-jak weekly 0.4 https://prohostf.smartnoticeboard.io/tag/jazz-pharmaceuticals-jazz weekly 0.4 https://prohostf.smartnoticeboard.io/tag/jennerex-biotherapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/jeune-aesthetics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/johnson-johnson-jnj weekly 0.4 https://prohostf.smartnoticeboard.io/tag/jounce-therapeutics-jnce weekly 0.4 https://prohostf.smartnoticeboard.io/tag/juno-therapeutics-juno weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kala-pharmaceuticals-kala weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kalobios-pharmaceuticals-inc-kbio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kalvista-pharmaceuticals-kalv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/karyopharm-therapeutics-inc-kpti weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kazia-therapeutics-ltd-kzia weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kempharm-inc-kmph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/keros-therapeutics-kros weekly 0.4 https://prohostf.smartnoticeboard.io/tag/keryx-biopharmaceuticals-inc-kerx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kilov-pharmaceuticals-ktov weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kiniksa-pharmaceuticals-knsa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kintara-therapeutics-ktra weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kintor-pharmaceutical-ltd-9939hk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kiora-pharmaceuticals-krpx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kirin-holdings weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kite-pharma-a-gilead-company weekly 0.4 https://prohostf.smartnoticeboard.io/tag/klotho-neurosciences-klto weekly 0.4 https://prohostf.smartnoticeboard.io/tag/krystal-biotech-krys weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ksq-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kura-oncology-kura weekly 0.4 https://prohostf.smartnoticeboard.io/tag/kymera-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/la-jolla-pharmaceutical-company-ljpc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/labcorp-lh weekly 0.4 https://prohostf.smartnoticeboard.io/tag/landos-biopharma-inc-labp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/lexaria-bioscience-lexx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/lexeo-therapeutics-lxeo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/lexicon-pharmaceuticals-lxrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/life-technologies-life weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ligand-pharmaceuticals-lgnd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/lineage-cell-therapeutics-lctx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/lipocine-lpcn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/longeveron-lgvn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/loxo-oncology-inc-loxo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/luminex-corporation-lmnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/macrogenics-mgnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/madrigal-pharmaceuticals-mdgl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mammoth-biosciences-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mannkind-corporation-mnkd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mapp-biopharmaceuticals-mapp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/maratin-capital-management weekly 0.4 https://prohostf.smartnoticeboard.io/tag/marinus-pharmaceuticals-mrns weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mars-symbioscience weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mast-therapeutics-inc-mstx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mateon-therapeutics-matn-oxgn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/maxcyte-inc-mxct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mckesson-corporation-mck weekly 0.4 https://prohostf.smartnoticeboard.io/tag/md-anderson weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mdxhealth-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/medicinova-mnov weekly 0.4 https://prohostf.smartnoticeboard.io/tag/medimmune-llc-medi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/medivation-mdvn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mei-pharma-inc-meip weekly 0.4 https://prohostf.smartnoticeboard.io/tag/memorial-sloan-kettering-msk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/merck-mrk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/merck-kgaa-darmstadt-germany weekly 0.4 https://prohostf.smartnoticeboard.io/tag/merrimack-pharmaceuticals-mack weekly 0.4 https://prohostf.smartnoticeboard.io/tag/merus-nv-mrus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mesoblast-limited-meso weekly 0.4 https://prohostf.smartnoticeboard.io/tag/metabolon-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/metamark-genetics-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/micromet-miti weekly 0.4 https://prohostf.smartnoticeboard.io/tag/milestone-mist weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mink-therapeutics-inkt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mirati-therapeutics-mrtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mirobio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mirum-pharmaceuticals-inc-mirm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mitomics-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mitsubishi-tanabe-pharma-corporation-mtpc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/moderna-inc-mrna weekly 0.4 https://prohostf.smartnoticeboard.io/tag/momenta-pharmaceuticals-mnta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/monopar-therapeutics-mnpr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/monsanto-co-mon weekly 0.4 https://prohostf.smartnoticeboard.io/tag/morphosys-mor weekly 0.4 https://prohostf.smartnoticeboard.io/tag/motif-bio-mtfb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/multiple-myeloma weekly 0.4 https://prohostf.smartnoticeboard.io/tag/mylan-myl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/myokardia-inc-myok weekly 0.4 https://prohostf.smartnoticeboard.io/tag/myovant-sciences-myov weekly 0.4 https://prohostf.smartnoticeboard.io/tag/myr-gmbh weekly 0.4 https://prohostf.smartnoticeboard.io/tag/myriad-genetics-inc-mygn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nabriva-therapeutics-nbrv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nanobiotix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nanoviricides-nnvc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nantkwest-nk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/navidea-biopharmaceuticals-navb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nektar-therapeutics-nktr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nestle-health-sciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/neuralstem-cur weekly 0.4 https://prohostf.smartnoticeboard.io/tag/neurizon-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/neurocrine-biosciences-nbix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/neuroderm-ltd-ndrm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/neuvivo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/newbridge-pharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/newlink-genetics-nlnk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ngm-biopharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nimbus-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/northwest-biotherapeutics-nwbo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nova-nordisk-nva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/novartis-nvs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/novarx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/novavax-nvax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/novo-nordisk-nvo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/novocure-nvcr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nps-pharmaceuticals-npsp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nurix-therapeutics-nrix weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nuvectis-pharma-nvct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nuvig-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nvidia-corporation-nvda weekly 0.4 https://prohostf.smartnoticeboard.io/tag/nymox-pharmaceutical-corp-nymx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/obagi-medical-products-ompi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/obseva-sa-obsv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ocugen-inc-ocgn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ocular-therapeutix-ocul weekly 0.4 https://prohostf.smartnoticeboard.io/tag/okyo-pharma-limited-okyo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/omeros-corporation-omer weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oncocyte-corporation-ocx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oncogenex-pharmaceuticals-inc-ogxi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oncolytics-biotech-oncy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oncore-biopharma weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oncothyreon-inc-onty weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ono-pharmaceutical weekly 0.4 https://prohostf.smartnoticeboard.io/tag/onyx-onxx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ophthotech-corporation-opht weekly 0.4 https://prohostf.smartnoticeboard.io/tag/opko-health-inc-opk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oppenheimer-co weekly 0.4 https://prohostf.smartnoticeboard.io/tag/optimer-optr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oramed-pharmaceuticals-ormp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/orchard-therapeutics-ortx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/orexigen-therapeutics-orex weekly 0.4 https://prohostf.smartnoticeboard.io/tag/orexo-ab-orxof weekly 0.4 https://prohostf.smartnoticeboard.io/tag/organovo-onvo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/orion-corporation weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oryon-cell-therapies weekly 0.4 https://prohostf.smartnoticeboard.io/tag/osi-osip weekly 0.4 https://prohostf.smartnoticeboard.io/tag/osiris-therapeutics-inc-osir weekly 0.4 https://prohostf.smartnoticeboard.io/tag/otsuka-pharmaceutical-co-ltd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ovid-therapeutics-ovid weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oxford-biotherapeutics-obt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oxford-nanopore weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oxford-university weekly 0.4 https://prohostf.smartnoticeboard.io/tag/oyster-point-pharma-inc-oyst weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pacific-biosciences-pacb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/paion-ag-pa8 weekly 0.4 https://prohostf.smartnoticeboard.io/tag/palatin-technologies-ptn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/paratek-pharmaceuticals-prtk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pepromene-bio-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/peregrine-pharmaceuticals-pphm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/perrigo-prgo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pfizer-pfe weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pharmacyclics-pcyc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pharmasset-inc-vrus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pieris-pharmaceuticals-pirs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pliant-therapeutics-plrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pluristem-therapeutics-psti weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pmv-pharmaceuticals-pmvp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/portola-pharmaceuticals-inc-ptla weekly 0.4 https://prohostf.smartnoticeboard.io/tag/poxel-biopharmaceutical weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prana-biotechnologys-pran weekly 0.4 https://prohostf.smartnoticeboard.io/tag/praxis-precision-medicines-prax weekly 0.4 https://prohostf.smartnoticeboard.io/tag/precigen-pgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/precision-biosciences-dtil weekly 0.4 https://prohostf.smartnoticeboard.io/tag/precision-biosciences-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prescription-drug-user-fee-act-pdufa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prilenia-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prima-biomed-pbmd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/progenics-pharmaceuticals-pgnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prohost-portfolio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prolor-biotech-pbth weekly 0.4 https://prohostf.smartnoticeboard.io/tag/promis-neurosciences-pmn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prosensa-holding-nv-rna weekly 0.4 https://prohostf.smartnoticeboard.io/tag/protalix-biotherapeutics-plx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/protein-design-pdli weekly 0.4 https://prohostf.smartnoticeboard.io/tag/proteostasis-therapeutics-pti weekly 0.4 https://prohostf.smartnoticeboard.io/tag/prothena-prta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/psioxus-therapeutics-psioxus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ptc-therapeutics-ptct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pulmotect-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/pyxis-oncology-pyxs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/qiagen-qgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/quest-diagnostics-dgx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/questcor-pharmaceuticals-qcor weekly 0.4 https://prohostf.smartnoticeboard.io/tag/radius-health-inc-rdus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rapamune-ridaforolimus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rapport-therapeutics-rapp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rapt-therapeutics-rapt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rbc-capital-markets weekly 0.4 https://prohostf.smartnoticeboard.io/tag/re weekly 0.4 https://prohostf.smartnoticeboard.io/tag/re weekly 0.4 https://prohostf.smartnoticeboard.io/tag/reata-pharmaceuticals-reta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/receptos-inc-rcpt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/recursion-pharmaceuticals-rxrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/regeneron-pharmaceuticals-regn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/regenxbio-rgnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/regulus-pharmaceuticals-rgls weekly 0.4 https://prohostf.smartnoticeboard.io/tag/renovorx-inc-rnxt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/repligen-corporation-rgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/revance-therapeutics-rvnc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/revlimid-lenolidamide weekly 0.4 https://prohostf.smartnoticeboard.io/tag/revolution-medicines-rvmd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rewrite-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rhythm-pharmaceuticals-inc-rytm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ribometrix-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ridgeback-biotherapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rigel-pharmaceuticals-rigl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rna weekly 0.4 https://prohostf.smartnoticeboard.io/tag/roche-rhhby weekly 0.4 https://prohostf.smartnoticeboard.io/tag/roche-roche weekly 0.4 https://prohostf.smartnoticeboard.io/tag/roche-holdings-ag-rog weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rochegenentech weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rocket-pharmaceuticals-rckt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/roivant-sciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/royalty-pharma-plc-rprx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/rubius-therapeutics-ruby weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sage-therapeutics-sage weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sagimet-biosciences-sgmt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/salix-pharmaceuticals-ltd-slxp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/salk-institute-for-biological-studies weekly 0.4 https://prohostf.smartnoticeboard.io/tag/samsung-ct-sct weekly 0.4 https://prohostf.smartnoticeboard.io/tag/samsung-electronics-sec weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sangamo-therapeutics-inc-sgmo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sanofi-sny weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sanofi-aventis-san weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sanofigenzyme weekly 0.4 https://prohostf.smartnoticeboard.io/tag/santarus-inc-snts weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sarepta-therapeutics-srpt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sars-cov-2-the-virus-that-causes-covid-19 weekly 0.4 https://prohostf.smartnoticeboard.io/tag/savient-svnt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/scholar-rock-srrk weekly 0.4 https://prohostf.smartnoticeboard.io/tag/schrodinger-sdgr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/seagen-inc-sgen weekly 0.4 https://prohostf.smartnoticeboard.io/tag/semma-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sentynl-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sequenom-sqnm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/seres-therapeutics-mcrb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/servier-laboratories weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shape-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shering-plough-sgp weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shionogi-limited weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shire-pharmaceuticals-shpg weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shockwave-medical-swav weekly 0.4 https://prohostf.smartnoticeboard.io/tag/shoreline-biosciences weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sinovac-sva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sirtex-medical-ltd-srx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/soleno-therapeutics-slno weekly 0.4 https://prohostf.smartnoticeboard.io/tag/solid-biosciences-inc-sldb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sonoma-pharmaceuticals-snoa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sophiris-bio-sphs weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sorrento-therapeutics-srne weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sparingvision weekly 0.4 https://prohostf.smartnoticeboard.io/tag/spark-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/spectrum-pharmaceuticals-sppi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/spero weekly 0.4 https://prohostf.smartnoticeboard.io/tag/spring-bank-pharmaceutical-sbph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/spyre-therapeutics-syre weekly 0.4 https://prohostf.smartnoticeboard.io/tag/stemcells-inc-stem weekly 0.4 https://prohostf.smartnoticeboard.io/tag/stemline-therapeutics-stml weekly 0.4 https://prohostf.smartnoticeboard.io/tag/stemsynergy-therapeutics-inc-ssti weekly 0.4 https://prohostf.smartnoticeboard.io/tag/stridebio-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/structure-therapeutics-gpcr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/summit-therapeutics-smmt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sunesis-pharmaceuticals-snss weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sunshine-biopharma-sbfm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/supernus-pharmaceuticals-supn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/sutro-biopharma-inc-stro weekly 0.4 https://prohostf.smartnoticeboard.io/tag/syndax-pharmaceuticals-sndx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/synta-pharmaceuticals-snta weekly 0.4 https://prohostf.smartnoticeboard.io/tag/synthetic-biologics-syn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/synthetic-genomics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/takeda-pharmaceutical-limited-tak weekly 0.4 https://prohostf.smartnoticeboard.io/tag/takeda-pharmaceutical-limited-tkpyy weekly 0.4 https://prohostf.smartnoticeboard.io/tag/takeda-pharmaceuticals-usa-inc-tpusa weekly 0.4 https://prohostf.smartnoticeboard.io/tag/takis-biotech-srl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tapimmune-tpiv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tasley-biopharmaceuticals weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tcr2-therapeutics-tcrr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tekmira-pharmaceuticals-corp-tkmr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/telaprevir weekly 0.4 https://prohostf.smartnoticeboard.io/tag/terns-pharmaceuticals-tern weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tesaro-inc-tsro weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tetralogic-pharmaceuticals-corp-tlog weekly 0.4 https://prohostf.smartnoticeboard.io/tag/teva-pharmaceutical-industries-ltd-teva weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tg-therapeutics-tgtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/the-barron-s weekly 0.4 https://prohostf.smartnoticeboard.io/tag/the-european-society-for-medical-oncology-esmo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/the-medicines-company-mdco weekly 0.4 https://prohostf.smartnoticeboard.io/tag/therapeutics-md-inc-txmd weekly 0.4 https://prohostf.smartnoticeboard.io/tag/theratechnologies-tsxth weekly 0.4 https://prohostf.smartnoticeboard.io/tag/theravance-biopharma-tbph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/theravance-inc-thrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/thermo-fisher-scientific-tmo weekly 0.4 https://prohostf.smartnoticeboard.io/tag/threshold-pharmaceuticals-inc-thld weekly 0.4 https://prohostf.smartnoticeboard.io/tag/transcept-pharmaceuticals-tspt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/transition-therapeutics-tthi weekly 0.4 https://prohostf.smartnoticeboard.io/tag/translate-bio-tbio weekly 0.4 https://prohostf.smartnoticeboard.io/tag/transmedics-group-tmdx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/trastuzumab-dm1 weekly 0.4 https://prohostf.smartnoticeboard.io/tag/travere-therapeutics-tvtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/treefrog-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/trevena-trvn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/trovagene-inc-trov weekly 0.4 https://prohostf.smartnoticeboard.io/tag/trxade-health-inc-meds weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tubulis weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tusk-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/tysabri weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ucb-pharmaceuticals-ucb weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ultragenyx-pharmaceutical-inc-rare weekly 0.4 https://prohostf.smartnoticeboard.io/tag/uniqure-qure weekly 0.4 https://prohostf.smartnoticeboard.io/tag/united-therapeutics-uthr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/urogen-pharma-urgn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vaccitech-plc-vacc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/valeant-pharmaceuticals-international-vrx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/valneva-se-valn weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vanda-pharmaceuticals-vnda weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vaxart-vxrt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vaxcyte-inc-pcvx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vaximm-ag weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vbi-vaccines-vbiv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vbl-therapeutics-vblt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vectory-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/velcade-bortezomib weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ventyx-biosciences-vtyx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vera-therapeutics-vera weekly 0.4 https://prohostf.smartnoticeboard.io/tag/veracyte-inc-vcyt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verastem-oncology-vstm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verily-life-sciences-llc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verinata-health-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verona-pharma-vrna weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verrica-pharmaceuticals-vrca weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vertex-pharmaceuticals-vrtx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/verve-therapeutics-verv weekly 0.4 https://prohostf.smartnoticeboard.io/tag/viacyte-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vical-inc-vicl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vicuron-pharmaceuticals-inc weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vifor weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vifor-pharma weekly 0.4 https://prohostf.smartnoticeboard.io/tag/viiv-healthcare weekly 0.4 https://prohostf.smartnoticeboard.io/tag/viking-therapeutics-vktx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vir-biotechnology-vir weekly 0.4 https://prohostf.smartnoticeboard.io/tag/viracta-therapeutics-virx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/viropharma-inc-vphm weekly 0.4 https://prohostf.smartnoticeboard.io/tag/virpax-pharmaceuticals-vrpx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/virta-health weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vitae-pharmaceuticals-vtae weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vivos-therapeutics-vvos weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vivus-vvus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/voyager-therapeutics-vygr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/vtv-therapeutics-vtvt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/wave-life-sciences-wve weekly 0.4 https://prohostf.smartnoticeboard.io/tag/werewolf-therapeutics-howl weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xbiotech-xbit weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xencor-xncr weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xenon-pharmaceuticals-xene weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xenoport-inc-xnpt weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xoma-xoma weekly 0.4 https://prohostf.smartnoticeboard.io/tag/xylocor-therapeutics weekly 0.4 https://prohostf.smartnoticeboard.io/tag/yuhan-corporation weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zaltrap weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zerenex weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zika-virus weekly 0.4 https://prohostf.smartnoticeboard.io/tag/ziopharm-oncology-ziop weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zogenix-inc-zgnx weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zosano-pharma-zsan weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zs-pharma-zsph weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zymeworks-zyme weekly 0.4 https://prohostf.smartnoticeboard.io/tag/zymeworks-inc-zyme weekly 0.4